US5550111A
(en)
*
|
1984-07-11 |
1996-08-27 |
Temple University-Of The Commonwealth System Of Higher Education |
Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
|
US5643889A
(en)
*
|
1984-07-11 |
1997-07-01 |
Temple University-Of The Commonwealth System Of Pennsylvania |
Cholesterol conjugates of 2'5'-oligoadenylate derivatives and antiviral uses thereof
|
US5108921A
(en)
*
|
1989-04-03 |
1992-04-28 |
Purdue Research Foundation |
Method for enhanced transmembrane transport of exogenous molecules
|
US7037646B1
(en)
|
1990-01-11 |
2006-05-02 |
Isis Pharmaceuticals, Inc. |
Amine-derivatized nucleosides and oligonucleosides
|
US6153737A
(en)
*
|
1990-01-11 |
2000-11-28 |
Isis Pharmaceuticals, Inc. |
Derivatized oligonucleotides having improved uptake and other properties
|
US6395492B1
(en)
*
|
1990-01-11 |
2002-05-28 |
Isis Pharmaceuticals, Inc. |
Derivatized oligonucleotides having improved uptake and other properties
|
US6114513A
(en)
|
1990-01-11 |
2000-09-05 |
Isis Pharmaceuticals, Inc. |
Thiol-derivatized oligonucleotides
|
US6753423B1
(en)
|
1990-01-11 |
2004-06-22 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
|
US20040142899A1
(en)
*
|
1990-01-11 |
2004-07-22 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
|
NZ244306A
(en)
*
|
1991-09-30 |
1995-07-26 |
Boehringer Ingelheim Int |
Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
|
US5981273A
(en)
*
|
1991-09-30 |
1999-11-09 |
Boehringer Ingelheim Int'l. Gmbh |
Composition comprising an endosomolytic agent for introducing nucleic acid complexes into higher eucaryotic cells
|
US5254342A
(en)
*
|
1991-09-30 |
1993-10-19 |
University Of Southern California |
Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
|
US6831166B2
(en)
*
|
1992-10-23 |
2004-12-14 |
Isis Pharmaceuticals, Inc. |
Derivatized oligonucleotides having improved uptake and other properties
|
US6335434B1
(en)
|
1998-06-16 |
2002-01-01 |
Isis Pharmaceuticals, Inc., |
Nucleosidic and non-nucleosidic folate conjugates
|
JPH07505283A
(en)
*
|
1992-03-20 |
1995-06-15 |
ベイラー・カレッジ・オブ・メディシン |
DNA transporter system and method of use
|
US6033884A
(en)
*
|
1992-03-20 |
2000-03-07 |
Baylor College Of Medicine |
Nucleic acid transporter systems and methods of use
|
US20020173474A1
(en)
*
|
1993-02-12 |
2002-11-21 |
President And Fellows Of Harvard College |
Methods & materials involving dimerization-mediated regulation of biological events
|
US5993860A
(en)
*
|
1993-06-17 |
1999-11-30 |
Venture Lending |
NSADI delivery employing a powdered hydrocolloid gum obtainable from higher plants
|
US6653458B1
(en)
|
1993-09-03 |
2003-11-25 |
Isis Pharmaceuticals, Inc. |
Modified oligonucleotides
|
AU679566B2
(en)
|
1993-09-03 |
1997-07-03 |
Isis Pharmaceuticals, Inc. |
Amine-derivatized nucleosides and oligonucleosides
|
US5635385A
(en)
*
|
1993-09-15 |
1997-06-03 |
Temple University-Of The Commonwealth System Of Higher Education |
Multi-unit ribozyme inhibition of oncogene gene expression
|
US5844107A
(en)
*
|
1994-03-23 |
1998-12-01 |
Case Western Reserve University |
Compacted nucleic acids and their delivery to cells
|
US6077835A
(en)
*
|
1994-03-23 |
2000-06-20 |
Case Western Reserve University |
Delivery of compacted nucleic acid to cells
|
US5972901A
(en)
*
|
1994-03-23 |
1999-10-26 |
Case Western Reserve University |
Serpin enzyme complex receptor--mediated gene transfer
|
ES2316148T3
(en)
*
|
1994-03-23 |
2009-04-01 |
Ohio University |
COMPACTED NUCLEIC ACIDS AND ITS SUPPLY TO CELLS.
|
WO1995030331A1
(en)
*
|
1994-05-05 |
1995-11-16 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of treating tumors
|
US5670347A
(en)
|
1994-05-11 |
1997-09-23 |
Amba Biosciences Llc |
Peptide-mediated gene transfer
|
WO1996012501A1
(en)
|
1994-10-19 |
1996-05-02 |
Human Genome Sciences, Inc. |
Human hypoxanthine-(guanine) phosphoribosyl transferase-2
|
IL114615A0
(en)
|
1995-07-16 |
1995-11-27 |
Yeda Res & Dev |
Modulators of the function of fas receptors and other proteins
|
JPH11511112A
(en)
|
1995-02-10 |
1999-09-28 |
ユニバーシティ・オブ・マサチューセッツ |
Delivery of exogenous compounds
|
US5846743A
(en)
*
|
1995-02-22 |
1998-12-08 |
Brigham And Women's Hospital, Inc. |
Polyphoshoinositide binding peptides for intracellular drug delivery
|
US5674748A
(en)
|
1995-03-14 |
1997-10-07 |
Thomas Jefferson University |
Human cyclin-dependent kinase-like proteins and methods of using the same
|
US5547668A
(en)
*
|
1995-05-05 |
1996-08-20 |
The Board Of Trustees Of The University Of Illinois |
Conjugates of folate anti-effector cell antibodies
|
US5672500A
(en)
*
|
1995-05-18 |
1997-09-30 |
Thomas Jefferson University |
Mch2, an apoptotic cysteine protease, and compositions for making and methods of using the same
|
US5817789A
(en)
*
|
1995-06-06 |
1998-10-06 |
Transkaryotic Therapies, Inc. |
Chimeric proteins for use in transport of a selected substance into cells
|
US6420549B1
(en)
|
1995-06-06 |
2002-07-16 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide analogs having modified dimers
|
US5912160A
(en)
*
|
1995-08-22 |
1999-06-15 |
Thomas Jefferson University |
Gab1, Grb2 binding protein, and compositions for making and methods of using the same
|
US20030119724A1
(en)
*
|
1995-11-22 |
2003-06-26 |
Ts`O Paul O.P. |
Ligands to enhance cellular uptake of biomolecules
|
CA2190304A1
(en)
*
|
1995-12-15 |
1997-06-16 |
Elazar Rabbani |
Property effecting and/or property exhibiting compositions for therapeutic and diagnostic uses
|
US20050025742A1
(en)
*
|
1996-01-08 |
2005-02-03 |
Canji, Inc. |
Methods and compositions for interferon therapy
|
US20040014709A1
(en)
*
|
1996-01-08 |
2004-01-22 |
Canji, Inc. |
Methods and compositions for interferon therapy
|
US5789244A
(en)
*
|
1996-01-08 |
1998-08-04 |
Canji, Inc. |
Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
|
US7002027B1
(en)
|
1996-01-08 |
2006-02-21 |
Canji, Inc. |
Compositions and methods for therapeutic use
|
US6344436B1
(en)
|
1996-01-08 |
2002-02-05 |
Baylor College Of Medicine |
Lipophilic peptides for macromolecule delivery
|
US6392069B2
(en)
|
1996-01-08 |
2002-05-21 |
Canji, Inc. |
Compositions for enhancing delivery of nucleic acids to cells
|
US6180767B1
(en)
|
1996-01-11 |
2001-01-30 |
Thomas Jefferson University |
Peptide nucleic acid conjugates
|
US6060587A
(en)
*
|
1996-01-29 |
2000-05-09 |
The Trustees Of The University Of Pennsylvania |
Cellular receptor for HIV-1 VPR essential for G2/M phase transition of the cell cycle
|
US5783566A
(en)
*
|
1996-05-10 |
1998-07-21 |
California Institute Of Technology |
Method for increasing or decreasing transfection efficiency
|
CA2174803C
(en)
*
|
1996-04-23 |
2000-07-11 |
Jonathan P. Wong |
Use of liposome encapsulated ciprofloxacin as an immunotherapeutic drug
|
US6261787B1
(en)
|
1996-06-03 |
2001-07-17 |
Case Western Reserve University |
Bifunctional molecules for delivery of therapeutics
|
US6072041A
(en)
*
|
1996-06-03 |
2000-06-06 |
Case Western Reserve University |
Fusion proteins for protein delivery
|
US6310052B1
(en)
|
1996-06-04 |
2001-10-30 |
Queen's University At Kingston |
Nitrate esters and their use for neurological conditions
|
JPH09324000A
(en)
*
|
1996-06-05 |
1997-12-16 |
Suntory Ltd |
Zygote of factor specifically recognizing interleukin2 receptor with ribonuclease
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
US20040171031A1
(en)
*
|
1996-06-06 |
2004-09-02 |
Baker Brenda F. |
Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
US20050042647A1
(en)
*
|
1996-06-06 |
2005-02-24 |
Baker Brenda F. |
Phosphorous-linked oligomeric compounds and their use in gene modulation
|
US7812149B2
(en)
|
1996-06-06 |
2010-10-12 |
Isis Pharmaceuticals, Inc. |
2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
|
US20070275921A1
(en)
*
|
1996-06-06 |
2007-11-29 |
Isis Pharmaceuticals, Inc. |
Oligomeric Compounds That Facilitate Risc Loading
|
US9096636B2
(en)
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
US20050119470A1
(en)
*
|
1996-06-06 |
2005-06-02 |
Muthiah Manoharan |
Conjugated oligomeric compounds and their use in gene modulation
|
US5980898A
(en)
|
1996-11-14 |
1999-11-09 |
The United States Of America As Represented By The U.S. Army Medical Research & Material Command |
Adjuvant for transcutaneous immunization
|
US20060002949A1
(en)
*
|
1996-11-14 |
2006-01-05 |
Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. |
Transcutaneous immunization without heterologous adjuvant
|
US20060002959A1
(en)
*
|
1996-11-14 |
2006-01-05 |
Government Of The United States |
Skin-sctive adjuvants for transcutaneous immuization
|
US6797276B1
(en)
|
1996-11-14 |
2004-09-28 |
The United States Of America As Represented By The Secretary Of The Army |
Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
|
AU7737196A
(en)
*
|
1996-11-14 |
1998-06-03 |
Brigham And Women's Hospital |
Polyphosphoinositide binding peptides for intracellular drug delivery
|
US6172043B1
(en)
|
1997-01-10 |
2001-01-09 |
Massachusetts Institute Of Technology |
Treatments for neurotoxicity in Alzheimer's disease caused by β amyloid peptides
|
US6942963B1
(en)
|
1997-01-10 |
2005-09-13 |
Massachusetts Institute Of Technology |
Methods for identifying treatments for neurotoxicity in Alzheimer's disease caused by β-amyloid peptides
|
ATE402717T1
(en)
|
1997-04-09 |
2008-08-15 |
Intellect Neurosciences Inc |
RECOMBINANT ANTIBODIES SPECIFIC TO BETA-AMYLOID TERMS, DNA CODING THEREFOR, AND METHOD FOR USE THEREOF
|
US6716625B1
(en)
|
1997-04-16 |
2004-04-06 |
Claude Selitrennikoff |
Histidine kinases of Aspergillus and other fungal species, related compositions, and methods of use
|
US6037461A
(en)
*
|
1997-05-20 |
2000-03-14 |
Thomas Jefferson University |
FADD-like anti-apoptotic molecules, methods of using the same, and compositions for and methods of making the same
|
AU731909B2
(en)
|
1997-07-01 |
2001-04-05 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for the delivery of oligonucleotides via the alimentary canal
|
ES2389519T3
(en)
|
1997-09-18 |
2012-10-26 |
The Trustees Of The University Of Pennsylvania |
Attenuated vif DNA immunization cassettes for genetic vaccines
|
AU1080899A
(en)
*
|
1997-10-14 |
1999-05-03 |
Nadine A. Tatton |
Methods for increasing schwann cell survival
|
US20040258703A1
(en)
*
|
1997-11-14 |
2004-12-23 |
The Government Of The Us, As Represented By The Secretary Of The Army |
Skin-active adjuvants for transcutaneous immunization
|
WO1999039744A1
(en)
*
|
1998-02-10 |
1999-08-12 |
The Ohio State University Research Foundation |
Compositions and methods for polynucleotide delivery
|
US20040002079A1
(en)
*
|
1998-02-11 |
2004-01-01 |
Gunn Robert B. |
Sodium-phosphate cotransporter in lithium therapy for the treatment of mental illness
|
US20020137786A1
(en)
*
|
1998-02-12 |
2002-09-26 |
William G. Tatton |
Deprenyl compounds to treat viral infections and reduce tissue damage associated therewith
|
US20090011984A1
(en)
*
|
1998-02-23 |
2009-01-08 |
Seppo Yla-Herttuala |
Biotin-binding receptor molecules
|
US6417168B1
(en)
|
1998-03-04 |
2002-07-09 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of treating tumors
|
US6329356B1
(en)
|
1998-04-10 |
2001-12-11 |
Neurochem, Inc. |
Phosphono-carboxylate compounds for treating amyloidosis
|
US6093382A
(en)
|
1998-05-16 |
2000-07-25 |
Bracco Research Usa Inc. |
Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
|
AU745880B2
(en)
*
|
1998-05-21 |
2002-04-11 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for non-parenteral delivery of oligonucleotides
|
US6300319B1
(en)
|
1998-06-16 |
2001-10-09 |
Isis Pharmaceuticals, Inc. |
Targeted oligonucleotide conjugates
|
US20030219427A1
(en)
*
|
1998-08-18 |
2003-11-27 |
Allen Hamish J. |
TPL-2/COT kinase and methods of use
|
US6077709A
(en)
|
1998-09-29 |
2000-06-20 |
Isis Pharmaceuticals Inc. |
Antisense modulation of Survivin expression
|
US6448078B1
(en)
|
1998-10-09 |
2002-09-10 |
The Trustees Of The University Of Pennsylvania |
Cellular receptor for HIV-1 Vpr essential for G2/M phase transition of the cell cycle
|
EP1131457B1
(en)
|
1998-11-19 |
2010-10-06 |
Georgetown University |
Systemic viral/ligand gene delivery system and gene therapy
|
US20050063950A1
(en)
*
|
1998-11-19 |
2005-03-24 |
Georgetown University |
Systemic viral/ligand gene delivery system and gene therapy
|
EP1140022B8
(en)
*
|
1998-12-18 |
2008-10-15 |
Hadasit Medical Research Services & Development Ltd. |
Method of administering a compound to multi-drug resistant cells
|
US6974698B1
(en)
|
1999-01-15 |
2005-12-13 |
The United States Of America As Represented By The Department Of Health And Human Services |
Methods for delivering biologically active molecules into cells
|
EP1216309A2
(en)
*
|
1999-03-01 |
2002-06-26 |
Variagenics, Inc. |
Methods for targeting rna molecules
|
US6713280B1
(en)
|
1999-04-07 |
2004-03-30 |
Thomas Jefferson University |
Enhancement of peptide cellular uptake
|
US7098192B2
(en)
|
1999-04-08 |
2006-08-29 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of STAT3 expression
|
JP4932086B2
(en)
*
|
1999-04-08 |
2012-05-16 |
インターセル ユーエスエイ、インコーポレイテッド |
Dry formulation for transcutaneous immunization
|
AU4282400A
(en)
*
|
1999-04-28 |
2000-11-10 |
Neurochem (International) Limited |
Compositions and methods for treating amyloidosis
|
US6609113B1
(en)
*
|
1999-05-03 |
2003-08-19 |
The Chase Manhattan Bank |
Method and system for processing internet payments using the electronic funds transfer network
|
AUPQ014699A0
(en)
*
|
1999-05-04 |
1999-05-27 |
Access Pharmaceuticals Australia Pty Limited |
Amplification of folate-mediated targeting to tumor cells using nanoparticles
|
US6562836B1
(en)
|
1999-05-24 |
2003-05-13 |
Queen's University Of Kingston |
Methods and compounds for inhibiting amyloid deposits
|
US6656730B1
(en)
*
|
1999-06-15 |
2003-12-02 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides conjugated to protein-binding drugs
|
JP2003505518A
(en)
*
|
1999-07-29 |
2003-02-12 |
ケース ウェスタン リザーブ ユニバーシティ |
Enhanced delivery via serpin enzyme complex receptor
|
EP2829609A1
(en)
|
1999-08-24 |
2015-01-28 |
E. R. Squibb & Sons, L.L.C. |
Human CTLA-4 antibodies and their uses
|
WO2001013958A2
(en)
*
|
1999-08-26 |
2001-03-01 |
Sydney Brenner |
Drug conjugates and methods of designing the same
|
US7067111B1
(en)
*
|
1999-10-25 |
2006-06-27 |
Board Of Regents, University Of Texas System |
Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
|
US6692724B1
(en)
|
1999-10-25 |
2004-02-17 |
Board Of Regents, The University Of Texas System |
Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
|
CA2391534A1
(en)
*
|
1999-11-15 |
2001-05-25 |
Drug Innovation & Design, Inc. |
Selective cellular targeting: multifunctional delivery vehicles
|
US8571975B1
(en)
|
1999-11-24 |
2013-10-29 |
Jpmorgan Chase Bank, N.A. |
System and method for sending money via E-mail over the internet
|
WO2001041784A1
(en)
*
|
1999-12-09 |
2001-06-14 |
The Regents Of The University Of California |
Methods and compositions for use in the treatment of filovirus mediated disease conditions
|
US6933108B2
(en)
*
|
1999-12-09 |
2005-08-23 |
The Regents Of The University Of California |
Methods and compositions for use in the treatment of filovirus mediated disease conditions
|
US6261840B1
(en)
|
2000-01-18 |
2001-07-17 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
US20020055479A1
(en)
|
2000-01-18 |
2002-05-09 |
Cowsert Lex M. |
Antisense modulation of PTP1B expression
|
JP2003525037A
(en)
*
|
2000-02-11 |
2003-08-26 |
リボザイム・ファーマシューティカルズ・インコーポレーテッド |
Methods and reagents for regulation and diagnosis of CD20 and NOGO gene expression
|
US8202979B2
(en)
*
|
2002-02-20 |
2012-06-19 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
|
US20030176385A1
(en)
*
|
2000-02-15 |
2003-09-18 |
Jingfang Ju |
Antisense modulation of protein expression
|
WO2001074382A1
(en)
*
|
2000-03-31 |
2001-10-11 |
Purdue Research Foundation |
Method of treatment using ligand-immunogen conjugates
|
CA2408594A1
(en)
|
2000-05-08 |
2001-11-15 |
Medarex, Inc. |
Human monoclonal antibodies to dendritic cells
|
US7560534B2
(en)
|
2000-05-08 |
2009-07-14 |
Celldex Research Corporation |
Molecular conjugates comprising human monoclonal antibodies to dendritic cells
|
US6680172B1
(en)
|
2000-05-16 |
2004-01-20 |
Regents Of The University Of Michigan |
Treatments and markers for cancers of the central nervous system
|
CA2410906C
(en)
*
|
2000-06-02 |
2012-10-02 |
Board Of Regents, The University Of Texas System |
Ethylenedicysteine (ec)-drug conjugates
|
US20080032942A1
(en)
*
|
2000-08-30 |
2008-02-07 |
Mcswiggen James |
RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
|
US20050209179A1
(en)
*
|
2000-08-30 |
2005-09-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
|
JP2004512345A
(en)
*
|
2000-11-02 |
2004-04-22 |
スミスクライン・ビーチャム・コーポレイション |
Receptor antagonist-lipid conjugates and delivery vehicles containing the same
|
WO2002035987A2
(en)
*
|
2000-11-03 |
2002-05-10 |
Massachusetts Institute Of Technology |
METHODS FOR IDENTIFYING TREATMENTS FOR NEUROTOXICITY IN ALZHEIMER'S DISEASE CAUSED BY β-AMYLOID PEPTIDES
|
US7067550B2
(en)
*
|
2000-11-03 |
2006-06-27 |
Massachusetts Institute Of Technology |
Treatments for neurotoxicity in Alzheimer's Disease
|
AU2002217980A1
(en)
|
2000-12-01 |
2002-06-11 |
Cell Works Inc. |
Conjugates of glycosylated/galactosylated peptide
|
WO2002064162A2
(en)
*
|
2001-02-13 |
2002-08-22 |
Government Of The United States, As Represented By The Secretary Of The Army |
Vaccine for transcutaneous immunization
|
US7875612B2
(en)
|
2001-04-24 |
2011-01-25 |
Purdue Research Foundation |
Folate mimetics and folate-receptor binding conjugates thereof
|
US20030003048A1
(en)
*
|
2001-04-26 |
2003-01-02 |
Chun Li |
Diagnostic imaging compositions, their methods of synthesis and use
|
US20060211642A1
(en)
*
|
2001-05-18 |
2006-09-21 |
Sirna Therapeutics, Inc. |
RNA inteference mediated inhibition of hepatitis C virus (HVC) gene expression using short interfering nucleic acid (siNA)
|
US20050182009A1
(en)
*
|
2001-05-18 |
2005-08-18 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of NF-Kappa B / REL-A gene expression using short interfering nucleic acid (siNA)
|
US20050080031A1
(en)
*
|
2001-05-18 |
2005-04-14 |
Sirna Therapeutics, Inc. |
Nucleic acid treatment of diseases or conditions related to levels of Ras, HER2 and HIV
|
US20050233996A1
(en)
*
|
2002-02-20 |
2005-10-20 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hairless (HR) gene expression using short interfering nucleic acid (siNA)
|
US20050124567A1
(en)
*
|
2001-05-18 |
2005-06-09 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of TRPM7 gene expression using short interfering nucleic acid (siNA)
|
US7517864B2
(en)
*
|
2001-05-18 |
2009-04-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20050176664A1
(en)
*
|
2001-05-18 |
2005-08-11 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering nucleic acid (siNA)
|
US20050130181A1
(en)
*
|
2001-05-18 |
2005-06-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of wingless gene expression using short interfering nucleic acid (siNA)
|
US20050256068A1
(en)
*
|
2001-05-18 |
2005-11-17 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of stearoyl-CoA desaturase (SCD) gene expression using short interfering nucleic acid (siNA)
|
US20040209831A1
(en)
*
|
2002-02-20 |
2004-10-21 |
Mcswiggen James |
RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (siNA)
|
US20050124566A1
(en)
*
|
2001-05-18 |
2005-06-09 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA)
|
US20050287128A1
(en)
*
|
2001-05-18 |
2005-12-29 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of TGF-beta and TGF-beta receptor gene expression using short interfering nucleic acid (siNA)
|
US20050164224A1
(en)
*
|
2001-05-18 |
2005-07-28 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of cyclin D1 gene expression using short interfering nucleic acid (siNA)
|
US20050176666A1
(en)
*
|
2001-05-18 |
2005-08-11 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of GPRA and AAA1 gene expression using short interfering nucleic acid (siNA)
|
US20070270579A1
(en)
*
|
2001-05-18 |
2007-11-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
|
US20050159380A1
(en)
*
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of angiopoietin gene expression using short interfering nucleic acid (siNA)
|
US20050164968A1
(en)
*
|
2001-05-18 |
2005-07-28 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of ADAM33 gene expression using short interfering nucleic acid (siNA)
|
US20050282188A1
(en)
*
|
2001-05-18 |
2005-12-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
|
US20050153915A1
(en)
*
|
2001-05-18 |
2005-07-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of early growth response gene expression using short interfering nucleic acid (siNA)
|
US20050164966A1
(en)
*
|
2001-05-18 |
2005-07-28 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of type 1 insulin-like growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20050222066A1
(en)
*
|
2001-05-18 |
2005-10-06 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20050227935A1
(en)
*
|
2001-05-18 |
2005-10-13 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of TNF and TNF receptor gene expression using short interfering nucleic acid (siNA)
|
US20070042983A1
(en)
*
|
2001-05-18 |
2007-02-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
|
US20030130186A1
(en)
*
|
2001-07-20 |
2003-07-10 |
Chandra Vargeese |
Conjugates and compositions for cellular delivery
|
US20050196767A1
(en)
*
|
2001-05-18 |
2005-09-08 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acis (siNA)
|
US20060142225A1
(en)
*
|
2001-05-18 |
2006-06-29 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of cyclin dependent kinase-2 (CDK2) gene expression using short interfering nucleic acid (siNA)
|
US20040198682A1
(en)
*
|
2001-11-30 |
2004-10-07 |
Mcswiggen James |
RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (siNA)
|
US20080188430A1
(en)
*
|
2001-05-18 |
2008-08-07 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA)
|
US20050014172A1
(en)
*
|
2002-02-20 |
2005-01-20 |
Ivan Richards |
RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA)
|
US20050191638A1
(en)
*
|
2002-02-20 |
2005-09-01 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
|
US20050196765A1
(en)
*
|
2001-05-18 |
2005-09-08 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of checkpoint Kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
|
US20050159379A1
(en)
*
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc |
RNA interference mediated inhibition of gastric inhibitory polypeptide (GIP) and gastric inhibitory polypeptide receptor (GIPR) gene expression using short interfering nucleic acid (siNA)
|
US20050187174A1
(en)
*
|
2001-05-18 |
2005-08-25 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA)
|
US20050079610A1
(en)
*
|
2001-05-18 |
2005-04-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of Fos gene expression using short interfering nucleic acid (siNA)
|
US20050164967A1
(en)
*
|
2001-05-18 |
2005-07-28 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA)
|
US20050182006A1
(en)
*
|
2001-05-18 |
2005-08-18 |
Sirna Therapeutics, Inc |
RNA interference mediated inhibition of protein kinase C alpha (PKC-alpha) gene expression using short interfering nucleic acid (siNA)
|
US20050159376A1
(en)
*
|
2002-02-20 |
2005-07-21 |
Slrna Therapeutics, Inc. |
RNA interference mediated inhibition 5-alpha reductase and androgen receptor gene expression using short interfering nucleic acid (siNA)
|
US20050119212A1
(en)
*
|
2001-05-18 |
2005-06-02 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of FAS and FASL gene expression using short interfering nucleic acid (siNA)
|
US20050182007A1
(en)
*
|
2001-05-18 |
2005-08-18 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
|
US20050136436A1
(en)
*
|
2001-05-18 |
2005-06-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of G72 and D-amino acid oxidase (DAAO) gene expression using short interfering nucleic acid (siNA)
|
US20050209180A1
(en)
*
|
2001-05-18 |
2005-09-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
|
US20050267058A1
(en)
*
|
2001-05-18 |
2005-12-01 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (sINA)
|
US20060142226A1
(en)
*
|
2001-05-18 |
2006-06-29 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of cholesteryl ester transfer protein (CETP) gene expression using short interfering nucleic acid (siNA)
|
US20050288242A1
(en)
*
|
2001-05-18 |
2005-12-29 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of RAS gene expression using short interfering nucleic acid (siNA)
|
US20050124568A1
(en)
*
|
2001-05-18 |
2005-06-09 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of acetyl-CoA-carboxylase gene expression using short interfering nucleic acid (siNA)
|
US20050153914A1
(en)
*
|
2001-05-18 |
2005-07-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of MDR P-glycoprotein gene expression using short interfering nucleic acid (siNA)
|
US20060241075A1
(en)
*
|
2001-05-18 |
2006-10-26 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of desmoglein gene expression using short interfering nucleic acid (siNA)
|
US20050159382A1
(en)
*
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
|
US20050203040A1
(en)
*
|
2001-05-18 |
2005-09-15 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
|
US20050119211A1
(en)
*
|
2001-05-18 |
2005-06-02 |
Sirna Therapeutics, Inc. |
RNA mediated inhibition connexin gene expression using short interfering nucleic acid (siNA)
|
US20050137155A1
(en)
*
|
2001-05-18 |
2005-06-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of Parkinson disease using short interfering nucleic acid (siNA)
|
US20050176665A1
(en)
*
|
2001-05-18 |
2005-08-11 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hairless (HR) gene expression using short interfering nucleic acid (siNA)
|
US20050233997A1
(en)
*
|
2001-05-18 |
2005-10-20 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
|
US20050143333A1
(en)
*
|
2001-05-18 |
2005-06-30 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
|
US20080161256A1
(en)
*
|
2001-05-18 |
2008-07-03 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
|
US20050054598A1
(en)
*
|
2002-02-20 |
2005-03-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition hairless (HR) gene expression using short interfering nucleic acid (siNA)
|
US20050233344A1
(en)
*
|
2001-05-18 |
2005-10-20 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of platelet derived growth factor (PDGF) and platelet derived growth factor receptor (PDGFR) gene expression using short interfering nucleic acid (siNA)
|
US20060019913A1
(en)
*
|
2001-05-18 |
2006-01-26 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibtion of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)
|
EP1992643A3
(en)
|
2001-06-20 |
2008-12-10 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US20050107595A1
(en)
*
|
2001-06-20 |
2005-05-19 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US7803915B2
(en)
*
|
2001-06-20 |
2010-09-28 |
Genentech, Inc. |
Antibody compositions for the diagnosis and treatment of tumor
|
CA2790034A1
(en)
|
2001-06-21 |
2003-01-03 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of superoxide dismutase 1, soluble expression
|
WO2003000201A2
(en)
*
|
2001-06-25 |
2003-01-03 |
Drug Innovation & Design, Incorporated |
Exponential pattern recognition based cellular targeting, compositions, methods and anticancer applications
|
US6964950B2
(en)
|
2001-07-25 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of C-reactive protein expression
|
US7425545B2
(en)
|
2001-07-25 |
2008-09-16 |
Isis Pharmaceuticals, Inc. |
Modulation of C-reactive protein expression
|
US20030096772A1
(en)
|
2001-07-30 |
2003-05-22 |
Crooke Rosanne M. |
Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
|
US7407943B2
(en)
|
2001-08-01 |
2008-08-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein B expression
|
US7227014B2
(en)
|
2001-08-07 |
2007-06-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein (a) expression
|
WO2003024392A2
(en)
|
2001-09-18 |
2003-03-27 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
ES2338305T3
(en)
*
|
2001-09-28 |
2010-05-06 |
Purdue Research Foundation |
TREATMENT METHOD THAT USES BINDING-IMMUNOGEN CONJUGATES.
|
NZ566396A
(en)
|
2001-10-09 |
2009-07-31 |
Isis Pharmaceuticals Inc |
Antisense modulation of insulin-like growth factor binding protein 5 expressions
|
US6750019B2
(en)
|
2001-10-09 |
2004-06-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of insulin-like growth factor binding protein 5 expression
|
WO2003088808A2
(en)
|
2002-04-16 |
2003-10-30 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
IL161733A0
(en)
|
2001-11-02 |
2005-11-20 |
Insert Therapeutics Inc |
Methods and compositions for therapeutic use of rna interference
|
US6965025B2
(en)
|
2001-12-10 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of connective tissue growth factor expression
|
US7255874B1
(en)
|
2001-12-21 |
2007-08-14 |
Closure Medical Corporation |
Biocompatible polymers and adhesives: compositions, methods of making and uses related thereto
|
US7261875B2
(en)
*
|
2001-12-21 |
2007-08-28 |
Board Of Regents, The University Of Texas System |
Dendritic poly (amino acid) carriers and methods of use
|
EP1575571A4
(en)
|
2002-01-02 |
2008-06-25 |
Genentech Inc |
Compositions and methods for the diagnosis and treatment of tumor
|
US20050222064A1
(en)
*
|
2002-02-20 |
2005-10-06 |
Sirna Therapeutics, Inc. |
Polycationic compositions for cellular delivery of polynucleotides
|
US20050096284A1
(en)
*
|
2002-02-20 |
2005-05-05 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
|
US20050137153A1
(en)
*
|
2002-02-20 |
2005-06-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of alpha-1 antitrypsin (AAT) gene expression using short interfering nucleic acid (siNA)
|
US20030191075A1
(en)
*
|
2002-02-22 |
2003-10-09 |
Cook Phillip Dan |
Method of using modified oligonucleotides for hepatic delivery
|
US20030180712A1
(en)
|
2002-03-20 |
2003-09-25 |
Biostratum Ab |
Inhibition of the beta3 subunit of L-type Ca2+ channels
|
DK2264172T3
(en)
|
2002-04-05 |
2017-11-27 |
Roche Innovation Ct Copenhagen As |
Oligomeric Compounds for Modulating HIF-1α Expression
|
AU2003224989B2
(en)
*
|
2002-04-19 |
2008-12-04 |
Endocyte, Inc. |
Adjuvant enhanced immunotherapy
|
US20030206916A1
(en)
*
|
2002-05-03 |
2003-11-06 |
Rush-Presbyterian-St. Luke's Medical Center |
Immunogenic peptides
|
US7199107B2
(en)
|
2002-05-23 |
2007-04-03 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of kinesin-like 1 expression
|
KR20120104412A
(en)
|
2002-09-06 |
2012-09-20 |
인설트 테라페틱스, 인코퍼레이티드 |
Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto
|
EP1537208A1
(en)
|
2002-09-13 |
2005-06-08 |
Replicor, Inc. |
Non-sequence complementary antiviral oligonucleotides
|
WO2004031350A2
(en)
|
2002-09-26 |
2004-04-15 |
Amgen, Inc. |
Modulation of forkhead box o1a expression
|
SI1558648T1
(en)
|
2002-10-17 |
2012-05-31 |
Genmab As |
Human monoclonal antibodies against cd20
|
WO2004110345A2
(en)
*
|
2002-10-29 |
2004-12-23 |
Pharmacia Corporation |
Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
|
WO2004044139A2
(en)
|
2002-11-05 |
2004-05-27 |
Isis Parmaceuticals, Inc. |
Modified oligonucleotides for use in rna interference
|
CA2504720C
(en)
|
2002-11-05 |
2013-12-24 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
CN101985443A
(en)
*
|
2002-11-07 |
2011-03-16 |
得克萨斯大学体系董事会 |
Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
|
JP2006515988A
(en)
*
|
2002-11-12 |
2006-06-15 |
ザ リサーチ ファンデーション オブ ステイト ユニバーシティ オブ ニューヨーク |
Translational regulation by non-translated small RNA (small, non-translatable RNA)
|
CA2505801A1
(en)
|
2002-11-13 |
2004-05-27 |
Rosanne Crooke |
Antisense modulation of apolipoprotein b expression
|
DK1569695T3
(en)
|
2002-11-13 |
2013-08-05 |
Genzyme Corp |
ANTISENSE MODULATION OF APOLIPOPROTEIN-B EXPRESSION
|
AU2002953073A0
(en)
*
|
2002-11-21 |
2003-01-16 |
Access Pharmaceuticals Australia Pty Limited |
Amplification of biotin-mediated targeting
|
DE10254601A1
(en)
|
2002-11-22 |
2004-06-03 |
Ganymed Pharmaceuticals Ag |
Gene products differentially expressed in tumors and their use
|
US7144999B2
(en)
|
2002-11-23 |
2006-12-05 |
Isis Pharmaceuticals, Inc. |
Modulation of hypoxia-inducible factor 1 alpha expression
|
US20040231231A1
(en)
*
|
2002-12-20 |
2004-11-25 |
Cataldo Dominic A. |
Use of colloidal clays for sustained release of active ingredients
|
TWI367096B
(en)
|
2003-01-27 |
2012-07-01 |
Endocyte Inc |
Vitamin-receptor binding drug delivery conjugates and pharmaceutical compositions
|
US7713738B2
(en)
|
2003-02-10 |
2010-05-11 |
Enzon Pharmaceuticals, Inc. |
Oligomeric compounds for the modulation of survivin expression
|
NZ541637A
(en)
|
2003-02-11 |
2008-07-31 |
Antisense Therapeutics Pty Ltd |
Modulation of insulin like growth factor I receptor
|
US7803781B2
(en)
|
2003-02-28 |
2010-09-28 |
Isis Pharmaceuticals, Inc. |
Modulation of growth hormone receptor expression and insulin-like growth factor expression
|
US20040185559A1
(en)
|
2003-03-21 |
2004-09-23 |
Isis Pharmaceuticals Inc. |
Modulation of diacylglycerol acyltransferase 1 expression
|
US7598227B2
(en)
|
2003-04-16 |
2009-10-06 |
Isis Pharmaceuticals Inc. |
Modulation of apolipoprotein C-III expression
|
AU2004231740A1
(en)
*
|
2003-04-17 |
2004-11-04 |
The Trustees Of Columbia University In The City Ofnew York |
Desmoglein 4 is a novel gene involved in hair growth
|
NZ542988A
(en)
|
2003-04-23 |
2008-07-31 |
Medarex Inc |
Humanised antibodies directed against the IFNAR-1 receptor in which murine CDR sequences have been grafted directly into unmodified human framework sequences, resulting in high affinity, functional antibodies
|
US7399853B2
(en)
|
2003-04-28 |
2008-07-15 |
Isis Pharmaceuticals |
Modulation of glucagon receptor expression
|
EP1622646B1
(en)
*
|
2003-05-06 |
2012-08-08 |
Purdue Research Foundation |
Treatment of lupus targeting the macrophages or the folate receptor
|
IL156263A0
(en)
*
|
2003-06-02 |
2004-01-04 |
Hadasit Med Res Service |
Livin-derived peptides, compositions and uses thereof
|
CN1984921B
(en)
|
2003-06-03 |
2010-06-16 |
Isis药物公司 |
Modulation of survivin expression
|
WO2005002508A2
(en)
*
|
2003-06-11 |
2005-01-13 |
Access Pharmaceuticals, Inc. |
Macromolecular platinum chelates
|
US20070010573A1
(en)
*
|
2003-06-23 |
2007-01-11 |
Xianqi Kong |
Methods and compositions for treating amyloid-related diseases
|
US7414076B2
(en)
*
|
2003-06-23 |
2008-08-19 |
Neurochem (International) Limited |
Methods and compositions for treating amyloid-related diseases
|
US20050142191A1
(en)
|
2003-06-23 |
2005-06-30 |
Neurochem (International) Limited |
Pharmaceutical formulations of amyloid inhibiting compounds
|
US7244764B2
(en)
*
|
2003-06-23 |
2007-07-17 |
Neurochem (International) Limited |
Methods and compositions for treating amyloid-related diseases
|
US7812116B2
(en)
*
|
2003-07-03 |
2010-10-12 |
Rush University Medical Center |
Immunogenic peptides
|
CA2533701A1
(en)
|
2003-07-31 |
2005-02-17 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and compositions for use in modulation of small non-coding rnas
|
US7825235B2
(en)
|
2003-08-18 |
2010-11-02 |
Isis Pharmaceuticals, Inc. |
Modulation of diacylglycerol acyltransferase 2 expression
|
US20070123480A1
(en)
*
|
2003-09-11 |
2007-05-31 |
Replicor Inc. |
Oligonucleotides targeting prion diseases
|
EP1668130A2
(en)
|
2003-09-18 |
2006-06-14 |
Isis Pharmaceuticals, Inc. |
Modulation of eif4e expression
|
ES2437491T3
(en)
|
2003-10-10 |
2014-01-10 |
Alchemia Oncology Pty Limited |
Modulation of the synthesis and degradation of hyaluronan in the treatment of disease
|
US20050191653A1
(en)
|
2003-11-03 |
2005-09-01 |
Freier Susan M. |
Modulation of SGLT2 expression
|
EP1689432B1
(en)
|
2003-11-17 |
2009-12-30 |
Genentech, Inc. |
Compositions and methods for the treatment of tumor of hematopoietic origin
|
US20050118124A1
(en)
*
|
2003-12-01 |
2005-06-02 |
Reinhart Gale M. |
Compositions for treating keratinous surfaces
|
US9050378B2
(en)
*
|
2003-12-10 |
2015-06-09 |
Board Of Regents, The University Of Texas System |
N2S2 chelate-targeting ligand conjugates
|
PL1691837T3
(en)
|
2003-12-10 |
2012-11-30 |
Squibb & Sons Llc |
Ip-10 antibodies and their uses
|
CA2546054C
(en)
|
2003-12-10 |
2014-05-13 |
Medarex, Inc. |
Interferon alpha antibodies and their uses
|
FR2864085B1
(en)
*
|
2003-12-18 |
2010-09-17 |
Centre Nat Rech Scient |
NEW MODULATORS OF PROTEASOME
|
KR20070006709A
(en)
|
2003-12-23 |
2007-01-11 |
산타리스 팔마 에이/에스 |
Oligomeric compounds for the modulation of bcl-2
|
EP2363480A3
(en)
|
2004-01-20 |
2015-10-07 |
Isis Pharmaceuticals, Inc. |
Modulation of glucocorticoid receptor expression
|
US7468431B2
(en)
|
2004-01-22 |
2008-12-23 |
Isis Pharmaceuticals, Inc. |
Modulation of eIF4E-BP2 expression
|
JP2007524412A
(en)
*
|
2004-01-22 |
2007-08-30 |
イムノメディクス, インコーポレイテッド |
Folic acid conjugates and complexes
|
US20060147946A1
(en)
*
|
2004-01-27 |
2006-07-06 |
Pinchas Akiva |
Novel calcium channel variants and methods of use thereof
|
AU2005214331B2
(en)
|
2004-02-12 |
2011-09-15 |
Eisai, Inc. |
Monoclonal antibodies that specifically bind to folate receptor alpha
|
US8569474B2
(en)
|
2004-03-09 |
2013-10-29 |
Isis Pharmaceuticals, Inc. |
Double stranded constructs comprising one or more short strands hybridized to a longer strand
|
WO2005089268A2
(en)
|
2004-03-15 |
2005-09-29 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for optimizing cleavage of rna by rnase h
|
DK1735323T3
(en)
|
2004-03-22 |
2017-12-11 |
Kode Biotech Ltd |
Synthetic Membrane Anchors
|
US10858384B2
(en)
|
2004-03-22 |
2020-12-08 |
Kode Biotech Limited |
Synthetic molecule constructs
|
JP5184077B2
(en)
*
|
2004-03-26 |
2013-04-17 |
キュリス,インコーポレイテッド |
RNA interference modulator of hedgehog signaling and use thereof
|
WO2006073419A2
(en)
*
|
2004-04-01 |
2006-07-13 |
Gang Zheng |
Lipoprotein nanoplatforms
|
US20050244869A1
(en)
*
|
2004-04-05 |
2005-11-03 |
Brown-Driver Vickie L |
Modulation of transthyretin expression
|
DE102004024617A1
(en)
|
2004-05-18 |
2005-12-29 |
Ganymed Pharmaceuticals Ag |
Differentially expressed in tumors gene products and their use
|
US20050287667A1
(en)
|
2004-06-01 |
2005-12-29 |
Pronai Therapeutics, Inc. |
Methods and compositions for the inhibition of gene expression
|
US20050272100A1
(en)
*
|
2004-06-02 |
2005-12-08 |
Arthur Karlin |
Separation and quantification of biotinylated macromolecules
|
US8394947B2
(en)
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
US20090048192A1
(en)
*
|
2004-06-03 |
2009-02-19 |
Isis Pharmaceuticals, Inc. |
Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
|
AU2004320622B2
(en)
*
|
2004-06-03 |
2012-06-14 |
Isis Pharmaceuticals, Inc. |
Chimeric gapped oligomeric compositions
|
AU2005252662B2
(en)
*
|
2004-06-03 |
2011-08-18 |
Isis Pharmaceuticals, Inc. |
Double strand compositions comprising differentially modified strands for use in gene modulation
|
EP2453024B1
(en)
|
2004-06-21 |
2017-12-06 |
The Board of Trustees of The Leland Stanford Junior University |
Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder
|
CA2570823C
(en)
|
2004-06-21 |
2015-02-24 |
Medarex, Inc. |
Interferon alpha receptor 1 antibodies and their uses
|
US7884086B2
(en)
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
JP5101288B2
(en)
|
2004-10-05 |
2012-12-19 |
カリフォルニア インスティテュート オブ テクノロジー |
Aptamer-regulated nucleic acids and uses thereof
|
US9447138B2
(en)
|
2004-11-09 |
2016-09-20 |
Roche Innovation Center Copenhagen A/S |
Potent LNA oligonucleotides for the inhibition of HIF-1a expression
|
BRPI0517613A
(en)
*
|
2004-11-09 |
2008-10-14 |
Santaris Pharma As |
oligonucleotides lna and cancer treatment
|
EP1833840B9
(en)
*
|
2004-11-09 |
2010-11-10 |
Santaris Pharma A/S |
Potent lna oligonucleotides for the inhibition of hif-1a
|
BRPI0517790A
(en)
*
|
2004-11-12 |
2008-10-21 |
Neurochem Int Ltd |
fluorinated methods and compositions for treating amyloid-related diseases
|
WO2006050611A1
(en)
|
2004-11-12 |
2006-05-18 |
The University Of British Columbia |
Antimicrobial peptides
|
EP1817305A2
(en)
*
|
2004-11-16 |
2007-08-15 |
Neurochem (International) Limited |
Compounds for the treatment of cns and amyloid associated diseases
|
EP1836161B1
(en)
|
2004-12-22 |
2016-07-20 |
BHI Limited Partnership |
Methods and compositions for treating amyloid-related diseases
|
EP1827239B1
(en)
*
|
2004-12-23 |
2019-04-17 |
Purdue Research Foundation |
Positron emission tomography imaging method
|
CA2596506C
(en)
|
2005-02-09 |
2021-04-06 |
Avi Biopharma, Inc. |
Antisense composition and method for treating muscle atrophy
|
CN101175769A
(en)
|
2005-03-10 |
2008-05-07 |
健泰科生物技术公司 |
Methods and compositions for modulating vascular integrity
|
CN101175757B
(en)
*
|
2005-03-16 |
2012-11-14 |
恩多塞特公司 |
Synthesis and purification of pteroic acid and conjugates thereof
|
SG10201912554TA
(en)
|
2005-03-23 |
2020-02-27 |
Genmab As |
Antibodies against cd38 for treatment of multiple myeloma
|
ES2381201T3
(en)
|
2005-03-31 |
2012-05-24 |
Calando Pharmaceuticals, Inc. |
Inhibitors of the subunit 2 of the ribonucleotide reductase and uses thereof
|
CA2607444C
(en)
*
|
2005-04-22 |
2015-03-10 |
Morphotek, Inc. |
Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
|
LT2439273T
(en)
|
2005-05-09 |
2019-05-10 |
Ono Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
|
CA2611814A1
(en)
|
2005-06-20 |
2007-01-04 |
Medarex, Inc. |
Cd19 antibodies and their uses
|
CN105330741B
(en)
|
2005-07-01 |
2023-01-31 |
E.R.施贵宝&圣斯有限责任公司 |
Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
|
US20090176725A1
(en)
*
|
2005-08-17 |
2009-07-09 |
Sirna Therapeutics Inc. |
Chemically modified short interfering nucleic acid molecules that mediate rna interference
|
KR20130113543A
(en)
*
|
2005-08-19 |
2013-10-15 |
엔도사이트, 인코포레이티드 |
Multi-drug ligand conjugates
|
US20080280937A1
(en)
*
|
2005-08-19 |
2008-11-13 |
Christopher Paul Leamon |
Ligand Conjugates of Vinca Alkaloids, Analogs, and Derivatives
|
US8507439B2
(en)
|
2005-08-29 |
2013-08-13 |
Angela Shashoua |
Neuroprotective and neurorestorative method and compositions
|
EP1762575A1
(en)
*
|
2005-09-12 |
2007-03-14 |
Ganymed Pharmaceuticals AG |
Identification of tumor-associated antigens for diagnosis and therapy
|
CA2622583A1
(en)
*
|
2005-09-15 |
2007-03-22 |
Henrik Frydenlund Hansen |
Rna antagonist compounds for the inhibition of apo-b100 expression
|
EP1934261B1
(en)
|
2005-09-26 |
2014-10-29 |
Medarex, L.L.C. |
Human monoclonal antibodies to cd70
|
EP2532679B1
(en)
|
2005-10-21 |
2017-04-12 |
Novartis AG |
Human antibodies against il13 and therapeutic uses
|
US20070099246A1
(en)
*
|
2005-11-03 |
2007-05-03 |
Sandy John D |
Antibodies, assays and kits to quantitate cartilage destruction
|
WO2007059064A2
(en)
|
2005-11-12 |
2007-05-24 |
The Board Of Trustees Of The Leland Stanford Junior University |
Fgf2-related methods for diagnosing and treating depression
|
WO2007062380A2
(en)
|
2005-11-21 |
2007-05-31 |
Isis Pharmaceuticals, Inc. |
Modulation of eif4e-bp2 expression
|
EP1790664A1
(en)
|
2005-11-24 |
2007-05-30 |
Ganymed Pharmaceuticals AG |
Monoclonal antibodies against claudin-18 for treatment of cancer
|
EP1971371B1
(en)
|
2005-12-01 |
2015-08-05 |
Pronai Therapeutics, Inc. |
Cancer therapies and pharmaceutical compositions used therein
|
PT1960434E
(en)
|
2005-12-08 |
2012-10-02 |
Medarex Inc |
Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1
|
IL173104A0
(en)
|
2006-01-12 |
2006-06-11 |
Yeda Res & Dev |
Siva and ubiquintination
|
US20090175886A1
(en)
|
2006-01-17 |
2009-07-09 |
Medarex, Inc. |
Monoclonal antibodies against cd30 lacking in fucosyl and xylosyl residues
|
EP3210633B1
(en)
|
2006-01-26 |
2019-06-19 |
Ionis Pharmaceuticals, Inc. |
Compositions and their uses directed to huntingtin
|
WO2007092299A2
(en)
*
|
2006-02-03 |
2007-08-16 |
Purdue Research Foundation |
Targeted conjugates and radiation
|
GB0603683D0
(en)
|
2006-02-23 |
2006-04-05 |
Novartis Ag |
Organic compounds
|
US20070232556A1
(en)
*
|
2006-03-31 |
2007-10-04 |
Montine Thomas J |
Methods and compositions for the treatment of neurological diseases and disorders
|
EP2614839A3
(en)
|
2006-04-05 |
2015-01-28 |
Genentech, Inc. |
Method for using BOC/CDO to modulate hedgehog signaling
|
US8758723B2
(en)
|
2006-04-19 |
2014-06-24 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods for cellular imaging and therapy
|
EP2021030A2
(en)
*
|
2006-04-21 |
2009-02-11 |
Amgen, Inc. |
Buffering agents for biopharmaceutical formulations
|
EP2027154B1
(en)
|
2006-04-21 |
2012-04-18 |
Amgen Inc. |
Immunoglobulin constant region domains with enhanced stability
|
US20070258941A1
(en)
*
|
2006-05-02 |
2007-11-08 |
Pfister Brian E |
Methods and compositions for remediation of disc herniation by modifying structure
|
US20070259820A1
(en)
*
|
2006-05-03 |
2007-11-08 |
The Regents Of The University Of Michigan |
Methods and reagents for activating heat shock protein 70
|
WO2007125173A2
(en)
*
|
2006-05-03 |
2007-11-08 |
Baltic Technology Development, Ltd. |
Antisense agents combining strongly bound base - modified oligonucleotide and artificial nuclease
|
WO2007139815A2
(en)
*
|
2006-05-23 |
2007-12-06 |
Purdue Research Foundation |
Imaging and therapeutic method using progenitor cells
|
EP2023938A4
(en)
*
|
2006-05-23 |
2010-11-10 |
Isis Pharmaceuticals Inc |
Modulation of chrebp expression
|
PE20080316A1
(en)
|
2006-05-25 |
2008-04-10 |
Bristol Myers Squibb Co |
AZIRIDINYL-EPOTILONE COMPOUNDS
|
PE20080102A1
(en)
*
|
2006-05-25 |
2008-02-11 |
Bristol Myers Squibb Co |
AZIRIDINYL-EPOTILONE CONJUGATES AND PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME
|
ES2286951B1
(en)
*
|
2006-05-26 |
2008-10-01 |
Instituto Cientifico Y Tecnologico De Navarra, S.A |
BIOADHESIVE NANOPARTICLES FOR THE ADMINISTRATION OF BIOLOGICALLY ACTIVE MOLECULES.
|
EP2193801B1
(en)
|
2006-06-28 |
2012-02-08 |
Yeda Research and Development Co. Ltd. |
Caspase-8 and wound healing
|
WO2008011473A2
(en)
|
2006-07-19 |
2008-01-24 |
Isis Pharmaceuticals, Inc. |
Compositions and their uses directed to hbxip
|
US20100316626A1
(en)
*
|
2006-08-11 |
2010-12-16 |
The Government Of The United States Of America As Represented By The Secretary |
Methods for treatment and diagnosis of psychiatric disorders
|
US20110182904A1
(en)
|
2006-09-05 |
2011-07-28 |
Deborah Zimmerman |
Antibodies to bone morphogenic proteins and receptors therefor and methods for their use
|
SG178712A1
(en)
|
2006-10-02 |
2012-03-29 |
Medarex Inc |
Human antibodies that bind cxcr4 and uses thereof
|
US10925977B2
(en)
|
2006-10-05 |
2021-02-23 |
Ceil>Point, LLC |
Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
|
EP2081553B1
(en)
*
|
2006-10-06 |
2020-08-12 |
Amgen Inc. |
Stable antibody formulations
|
PT3851447T
(en)
|
2006-10-12 |
2023-12-11 |
Bellus Health Inc |
Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
|
EP2094247B1
(en)
*
|
2006-10-20 |
2022-06-29 |
Amgen Inc. |
Stable polypeptide formulations
|
US8618248B2
(en)
|
2006-10-31 |
2013-12-31 |
President And Fellows Of Harvard College |
Phosphopeptide compositions and anti-phosphopeptide antibody compositions and methods of detecting phosphorylated peptides
|
US8158595B2
(en)
|
2006-11-09 |
2012-04-17 |
California Institute Of Technology |
Modular aptamer-regulated ribozymes
|
MX2009005189A
(en)
|
2006-11-15 |
2009-06-30 |
Medarex Inc |
Human monoclonal antibodies to btla and methods of use.
|
MX2009005776A
(en)
|
2006-12-01 |
2009-06-10 |
Medarex Inc |
Human antibodies that bind cd22 and uses thereof.
|
CL2007003622A1
(en)
|
2006-12-13 |
2009-08-07 |
Medarex Inc |
Human anti-cd19 monoclonal antibody; composition comprising it; and tumor cell growth inhibition method.
|
WO2008074004A2
(en)
|
2006-12-14 |
2008-06-19 |
Medarex, Inc. |
Human antibodies that bind cd70 and uses thereof
|
EP2118118B1
(en)
*
|
2007-01-19 |
2017-09-27 |
Exiqon A/S |
Mediated cellular delivery of lna oligonucleotides
|
JP2010516625A
(en)
|
2007-01-24 |
2010-05-20 |
インサート セラピューティクス, インコーポレイテッド |
Polymer-drug conjugates with tether groups for controlled drug delivery
|
WO2008094945A2
(en)
|
2007-01-29 |
2008-08-07 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating protein expression
|
WO2009045469A2
(en)
|
2007-10-02 |
2009-04-09 |
Amgen Inc. |
Increasing erythropoietin using nucleic acids hybridizable to micro-rna and precursors thereof
|
PL2716301T3
(en)
|
2007-02-16 |
2017-10-31 |
Merrimack Pharmaceuticals Inc |
Antibodies against erbb3 and uses thereof
|
WO2008101231A2
(en)
*
|
2007-02-16 |
2008-08-21 |
Endocyte, Inc. |
Methods and compositions for treating and diagnosing kidney disease
|
US7875431B2
(en)
|
2007-02-22 |
2011-01-25 |
Genentech, Inc. |
Methods for detecting inflammatory bowel disease
|
EP1970384A1
(en)
*
|
2007-03-14 |
2008-09-17 |
Ganymed Pharmaceuticals AG |
Monoclonal antibodies for treatment of cancer
|
JP5779350B2
(en)
|
2007-03-27 |
2015-09-16 |
シー レーン バイオテクノロジーズ, エルエルシー |
Constructs and libraries containing antibody surrogate light chain sequences
|
GB2463584B
(en)
*
|
2007-04-27 |
2012-02-01 |
Kode Biotech Ltd |
Carbohydrate-lipid constructs and their use in preventing or treating viral infection
|
WO2008147526A1
(en)
|
2007-05-23 |
2008-12-04 |
The Trustees Of The University Of Pennsylvania |
Targeted carriers for intracellular drug delivery
|
CA2688308A1
(en)
*
|
2007-05-25 |
2008-12-04 |
Purdue Research Foundation |
Method of imaging localized infections
|
WO2008147941A1
(en)
*
|
2007-05-25 |
2008-12-04 |
Bristol-Myers Squibb Company |
Processes for making epothilone compounds and analogs
|
EP1997832A1
(en)
|
2007-05-29 |
2008-12-03 |
Ganymed Pharmaceuticals AG |
Monoclonal antibodies against Claudin-18 for treatment of cancer
|
WO2009011855A2
(en)
*
|
2007-07-16 |
2009-01-22 |
California Institute Of Technology |
Selection of nucleic acid-based sensor domains within nucleic acid switch platform
|
JP2010535032A
(en)
|
2007-07-31 |
2010-11-18 |
メディミューン,エルエルシー |
Multispecific epitope binding proteins and uses thereof
|
US9693539B2
(en)
|
2007-08-10 |
2017-07-04 |
E. R. Squibb & Sons, L.L.C. |
HCO32 and HCO27 and related examples
|
US8367815B2
(en)
*
|
2007-08-28 |
2013-02-05 |
California Institute Of Technology |
Modular polynucleotides for ligand-controlled regulatory systems
|
US20120165387A1
(en)
|
2007-08-28 |
2012-06-28 |
Smolke Christina D |
General composition framework for ligand-controlled RNA regulatory systems
|
US8394391B2
(en)
*
|
2007-08-31 |
2013-03-12 |
University Of Utah Research Foundation |
Drug delivery vehicle that mimics viral properties
|
US8415455B2
(en)
|
2007-09-04 |
2013-04-09 |
Compugen Ltd |
Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
|
US8865667B2
(en)
*
|
2007-09-12 |
2014-10-21 |
California Institute Of Technology |
Higher-order cellular information processing devices
|
AR068767A1
(en)
|
2007-10-12 |
2009-12-02 |
Novartis Ag |
ANTIBODIES AGAINST SCLEROSTIN, COMPOSITIONS AND METHODS OF USE OF THESE ANTIBODIES TO TREAT A PATHOLOGICAL DISORDER MEDIATIONED BY SCLEROSTIN
|
DK2567709T3
(en)
|
2007-11-02 |
2018-03-12 |
Novartis Ag |
Molecules and Methods for Modulating Low-Density Lipoprotein Receptor-Related Protein 6 (LRP6)
|
CA2704560A1
(en)
*
|
2007-11-05 |
2009-05-14 |
Baltic Technology Development, Ltd. |
Use of oligonucleotides with modified bases in hybridization of nucleic acids
|
NZ585556A
(en)
|
2007-11-07 |
2012-07-27 |
Celldex Therapeutics Inc |
Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
|
CN101903037A
(en)
*
|
2007-11-15 |
2010-12-01 |
恩多塞特公司 |
Method of administering conjugates
|
CN101925364B
(en)
|
2007-11-27 |
2014-04-30 |
不列颠哥伦比亚大学 |
14-3-3 antagonists for prevention and treatment of arthritis
|
US9029524B2
(en)
*
|
2007-12-10 |
2015-05-12 |
California Institute Of Technology |
Signal activated RNA interference
|
AU2009205995B2
(en)
|
2008-01-18 |
2014-04-03 |
Medimmune, Llc |
Cysteine engineered antibodies for site-specific conjugation
|
US8039596B2
(en)
|
2008-02-05 |
2011-10-18 |
Bristol-Myers Squibb Company |
Alpha 5-beta 1 antibodies and their uses
|
CN101952454B
(en)
|
2008-02-08 |
2014-06-04 |
米迪缪尼有限公司 |
Anti-IFNAR1 antibodies with reduced Fc ligand affinity
|
WO2009108340A2
(en)
|
2008-02-27 |
2009-09-03 |
Temple University - Of The Commonwealth System Of Higher Education |
Leptin agonist and methods of use
|
EP2257301B1
(en)
|
2008-03-03 |
2014-01-22 |
The University of Miami |
Allogeneic cancer cell-based immunotherapy
|
CA2718884C
(en)
|
2008-03-20 |
2016-11-22 |
University Of Miami |
Heat shock protein gp96 vaccination and methods of using same
|
US8114983B2
(en)
|
2008-04-04 |
2012-02-14 |
Calando Pharmaceuticals, Inc. |
Compositions and use of EPAS1 inhibitors
|
US10485879B2
(en)
|
2008-04-15 |
2019-11-26 |
Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health |
Plasma cell cytokine vehicle containing fusion proteins for targeted introduction of siRNA into cells and tissues
|
EP2274331B1
(en)
|
2008-05-02 |
2013-11-06 |
Novartis AG |
Improved fibronectin-based binding molecules and uses thereof
|
CA2725911A1
(en)
|
2008-05-30 |
2009-12-23 |
Dana-Farber Cancer Institute, Inc. |
Methods of treating a meiotic kinesin-associated disease
|
WO2010008582A2
(en)
|
2008-07-18 |
2010-01-21 |
Rxi Pharmaceuticals Corporation |
Phagocytic cell drug delivery system
|
US20110237646A1
(en)
*
|
2008-08-07 |
2011-09-29 |
Isis Pharmaceuticals, Inc. |
Modulation of transthyretin expression for the treatment of cns related disorders
|
AR072999A1
(en)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
|
EP3081648A1
(en)
|
2008-08-25 |
2016-10-19 |
Excaliard Pharmaceuticals, Inc. |
Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
|
EP2166021A1
(en)
|
2008-09-16 |
2010-03-24 |
Ganymed Pharmaceuticals AG |
Monoclonal antibodies for treatment of cancer
|
US10138485B2
(en)
|
2008-09-22 |
2018-11-27 |
Rxi Pharmaceuticals Corporation |
Neutral nanotransporters
|
ES2592216T3
(en)
|
2008-09-26 |
2016-11-28 |
Dana-Farber Cancer Institute, Inc. |
Human anti-PD-1, PD-L1 and PD-L2 antibodies and their uses
|
US20110178024A1
(en)
|
2008-09-29 |
2011-07-21 |
Ben Gurion University Of The Negev Research And Development Authority |
Amyloid beta-peptides and methods of use thereof
|
US20110294870A1
(en)
|
2008-12-04 |
2011-12-01 |
Opko Curna, Llc |
Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
|
ES2629630T3
(en)
|
2008-12-04 |
2017-08-11 |
Curna, Inc. |
Treatment of diseases related to erythropoietin (EPO) by inhibiting the natural antisense transcript to EPO
|
CN102307997B
(en)
|
2008-12-04 |
2018-03-30 |
库尔纳公司 |
By suppressing to treat the related disease of Sirtuin 1 (SIRT1) for the natural antisense transcript of Sirtuin 1
|
AU2009325878B2
(en)
|
2008-12-08 |
2014-01-16 |
Compugen Ltd. |
TMEM154 polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
|
WO2010078536A1
(en)
|
2009-01-05 |
2010-07-08 |
Rxi Pharmaceuticals Corporation |
Inhibition of pcsk9 through rnai
|
US9745574B2
(en)
|
2009-02-04 |
2017-08-29 |
Rxi Pharmaceuticals Corporation |
RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
|
ES2762610T3
(en)
|
2009-02-12 |
2020-05-25 |
Curna Inc |
Treatment of diseases related to brain-derived neurotrophic factor (BDNF) by inhibition of natural antisense transcript for BDNF
|
CN102439149B
(en)
|
2009-02-12 |
2018-01-02 |
库尔纳公司 |
By suppressing to treat the related diseases of GDNF for the natural antisense transcript of the glial derived neurotrophic factor (GDNF)
|
US8329882B2
(en)
|
2009-02-18 |
2012-12-11 |
California Institute Of Technology |
Genetic control of mammalian cells with synthetic RNA regulatory systems
|
ES2845644T3
(en)
|
2009-03-04 |
2021-07-27 |
Curna Inc |
Treatment of sirtuin1-related diseases (SIRT1) by inhibition of the natural antisense transcript to sirtuin 1
|
BRPI1009232B1
(en)
|
2009-03-05 |
2022-05-03 |
E.R. Squibb & Sons, Llc. |
Isolated monoclonal antibody or an antigen-binding portion thereof, or an antibody fragment, composition comprising them, nucleic acid molecule, hybridoma and methods for preparing an anti-cadm1 antibody
|
MX2011009751A
(en)
|
2009-03-16 |
2011-09-29 |
Opko Curna Llc |
Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2.
|
WO2010107740A2
(en)
|
2009-03-17 |
2010-09-23 |
Curna, Inc. |
Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
|
EP2408913B1
(en)
|
2009-03-18 |
2016-12-14 |
Oncotherapy Science, Inc. |
Neil3 peptides and vaccines including the same
|
US9145555B2
(en)
|
2009-04-02 |
2015-09-29 |
California Institute Of Technology |
Integrated—ligand-responsive microRNAs
|
SG10201401604VA
(en)
|
2009-04-20 |
2014-08-28 |
Oxford Biotherapeutics Ltd |
Antibodies Specific To Cadherin-17
|
EP3524275A1
(en)
|
2009-04-22 |
2019-08-14 |
Massachusetts Institute Of Technology |
Innate immune supression enables repeated delivery of long rna molecules
|
JP5766179B2
(en)
|
2009-04-27 |
2015-08-19 |
ノバルティス アーゲー |
Compositions and methods for increasing muscle growth
|
MX2011011338A
(en)
|
2009-04-27 |
2012-04-19 |
Novartis Ag |
Composition and methods of use for therapeutic antibodies specific for the il-12 receptore betal subunit.
|
EP2424987B1
(en)
|
2009-05-01 |
2017-11-15 |
CuRNA, Inc. |
Treatment of hemoglobin (hbf/hbg) related diseases by inhibition of natural antisense transcript to hbf/hbg
|
UY32608A
(en)
|
2009-05-04 |
2010-12-31 |
Pangenetics 110 B V |
ANTIBODIES AGAINST THE NERVOUS GROWTH FACTOR (NGF) WITH IMPROVED LIVE STABILITY
|
CN102459596B
(en)
|
2009-05-06 |
2016-09-07 |
库尔纳公司 |
By suppression therapy lipid transfer and the metabolic gene relevant disease of the natural antisense transcript for lipid transfer and metabolic gene
|
JP6250930B2
(en)
|
2009-05-06 |
2017-12-20 |
クルナ・インコーポレーテッド |
Treatment of TTP-related diseases by suppression of natural antisense transcripts against tristetraproline (TTP)
|
US20120128671A1
(en)
|
2009-05-13 |
2012-05-24 |
Lawrence Horowitz |
Neutralizing molecules to influenza viruses
|
CN102575251B
(en)
|
2009-05-18 |
2018-12-04 |
库尔纳公司 |
The relevant disease of the reprogramming factor is treated by inhibiting the natural antisense transcript for the reprogramming factor
|
WO2011019423A2
(en)
|
2009-05-20 |
2011-02-17 |
Schering Corporation |
Modulation of pilr receptors to treat microbial infections
|
KR101703695B1
(en)
|
2009-05-22 |
2017-02-08 |
큐알엔에이, 인크. |
Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3
|
TWI507204B
(en)
|
2009-05-26 |
2015-11-11 |
Oncotherapy Science Inc |
Cdc45l peptides and vaccines including the same
|
CN103221541B
(en)
|
2009-05-28 |
2017-03-01 |
库尔纳公司 |
Antiviral gene relevant disease is treated by the natural antisense transcript suppressing antiviral gene
|
WO2010148050A2
(en)
|
2009-06-16 |
2010-12-23 |
Curna, Inc. |
Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
|
KR101702689B1
(en)
|
2009-06-16 |
2017-02-06 |
큐알엔에이, 인크. |
Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1
|
WO2011005481A1
(en)
|
2009-06-22 |
2011-01-13 |
Medimmune, Llc |
ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
|
CA2765889A1
(en)
|
2009-06-24 |
2010-12-29 |
Opko Curna, Llc |
Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
|
CA2765815A1
(en)
|
2009-06-26 |
2010-12-29 |
Opko Curna, Llc |
Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
|
US8394922B2
(en)
|
2009-08-03 |
2013-03-12 |
Medarex, Inc. |
Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
|
US9234199B2
(en)
|
2009-08-05 |
2016-01-12 |
Curna, Inc. |
Treatment of insulin gene (INS) related diseases by inhibition of natural antisense transcript to an insulin gene (INS)
|
CN102482671B
(en)
|
2009-08-25 |
2017-12-01 |
库尔纳公司 |
IQGAP relevant diseases are treated by suppressing the natural antisense transcript of ' gtpase activating protein containing IQ die bodys ' (IQGAP)
|
US20110059111A1
(en)
|
2009-09-01 |
2011-03-10 |
Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center |
Mammalian receptors as targets for antibody and active vaccination therapy against mold infections
|
US9321823B2
(en)
|
2009-09-02 |
2016-04-26 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
WO2011029823A1
(en)
|
2009-09-09 |
2011-03-17 |
Novartis Ag |
Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
|
CA2780741C
(en)
|
2009-10-12 |
2023-04-04 |
Smith Holdings, Llc |
Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
|
EP2470569A1
(en)
|
2009-10-13 |
2012-07-04 |
Oxford Biotherapeutics Ltd. |
Antibodies against epha10
|
BR112012009409A2
(en)
|
2009-10-22 |
2017-02-21 |
Genentech Inc |
method of identifying an inhibitory substance, antagonist molecule, isolated nucleic acid, vector, host cell, method of making the molecule, composition, article of manufacture, method of inhibiting a biological activity, method of treating a pathological condition, method for detect msp in a sample and method to detect hepsin in a sample
|
WO2011051327A2
(en)
|
2009-10-30 |
2011-05-05 |
Novartis Ag |
Small antibody-like single chain proteins
|
WO2011051466A1
(en)
|
2009-11-02 |
2011-05-05 |
Novartis Ag |
Anti-idiotypic fibronectin-based binding molecules and uses thereof
|
US20120244169A1
(en)
|
2009-11-06 |
2012-09-27 |
Fibrogen, Inc. |
Treatment for Radiation-Induced Disorders
|
CN102781237A
(en)
*
|
2009-11-23 |
2012-11-14 |
天蓝制药公司 |
Cyclodextrin-based polymers for therapeutic delivery
|
AR079217A1
(en)
|
2009-11-30 |
2012-01-04 |
Genentech Inc |
COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TUMOR TREATMENT
|
US9428586B2
(en)
|
2009-12-01 |
2016-08-30 |
Compugen Ltd |
Heparanase splice variant
|
MX2012006580A
(en)
|
2009-12-11 |
2012-09-28 |
Genecode As |
Methods of facilitating neural cell survival using gdnf family ligand (gfl) mimetics or ret signaling pathway activators.
|
TW201136604A
(en)
|
2009-12-14 |
2011-11-01 |
Oncotherapy Science Inc |
TMEM22 peptides and vaccines including the same
|
ES2661813T3
(en)
|
2009-12-16 |
2018-04-04 |
Curna, Inc. |
Treatment of diseases related to membrane transcription factor peptidase, site 1 (mbtps1) by inhibition of the natural antisense transcript to the mbtps1 gene
|
WO2011084357A1
(en)
|
2009-12-17 |
2011-07-14 |
Schering Corporation |
Modulation of pilr to treat immune disorders
|
US8293718B2
(en)
|
2009-12-18 |
2012-10-23 |
Novartis Ag |
Organic compositions to treat HSF1-related diseases
|
US9068183B2
(en)
|
2009-12-23 |
2015-06-30 |
Curna, Inc. |
Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2
|
CA2782373C
(en)
|
2009-12-23 |
2019-03-26 |
Opko Curna, Llc |
Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf
|
WO2011090740A2
(en)
|
2009-12-29 |
2011-07-28 |
Opko Curna, Llc |
Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
|
ES2585829T3
(en)
|
2009-12-29 |
2016-10-10 |
Curna, Inc. |
Treatment of diseases related to tumor protein 63 (p63) by inhibition of natural antisense transcription to p63
|
KR101878501B1
(en)
|
2010-01-04 |
2018-08-07 |
큐알엔에이, 인크. |
Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8
|
EP2521785B1
(en)
|
2010-01-06 |
2022-03-09 |
CuRNA, Inc. |
Inhibition of natural antisense transcript to a pancreatic developmental gene for use in a treatment of pancreatic developmental gene related diseases
|
DK2524039T3
(en)
|
2010-01-11 |
2018-03-12 |
Curna Inc |
TREATMENT OF GENDER HORMON-BINDING GLOBULIN (SHBG) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS TO SHBG
|
US8883739B2
(en)
|
2010-01-19 |
2014-11-11 |
The Trustees Of Columbia University In The City Of New York |
Osteocalcin as a treatment for male reproductive disorders
|
CN102782135A
(en)
|
2010-01-25 |
2012-11-14 |
库尔纳公司 |
Treatment of RNase H1 related diseases by inhibition of natural antisense transcript to RNase H1
|
WO2011092233A1
(en)
|
2010-01-29 |
2011-08-04 |
Novartis Ag |
Yeast mating to produce high-affinity combinations of fibronectin-based binders
|
MX2012009318A
(en)
|
2010-02-10 |
2012-09-07 |
Novartis Ag |
Methods and compounds for muscle growth.
|
CN102844435B
(en)
|
2010-02-22 |
2017-05-10 |
库尔纳公司 |
Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
|
MX2012009215A
(en)
|
2010-02-23 |
2012-11-23 |
Genentech Inc |
Compositions and methods for the diagnosis and treatment of tumor.
|
TW202348631A
(en)
|
2010-02-24 |
2023-12-16 |
美商免疫遺傳股份有限公司 |
Folate receptor 1 antibodies and immunoconjugates and uses thereof
|
CA2792910A1
(en)
|
2010-03-11 |
2011-09-15 |
Yusuke Nakamura |
Hjurp peptides and vaccines including the same
|
US20110256135A1
(en)
|
2010-03-17 |
2011-10-20 |
Wolfgang Fraunhofer |
Anti-nerve growth factor (ngf) antibody compositions
|
EP2371864A1
(en)
|
2010-03-23 |
2011-10-05 |
Ganymed Pharmaceuticals AG |
Monoclonal antibodies for treatment of cancer
|
RU2615143C2
(en)
|
2010-03-24 |
2017-04-04 |
Адвирна |
Self-delivered rnai compounds of reduced size
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
US9631018B2
(en)
|
2010-03-26 |
2017-04-25 |
The Trustees Of Dartmouth College |
Vista regulatory T cell mediator protein, vista binding agents and use thereof
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
TW201627003A
(en)
|
2010-04-02 |
2016-08-01 |
腫瘤療法 科學股份有限公司 |
ECT2 peptides and vaccines including the same
|
RU2610661C2
(en)
|
2010-04-09 |
2017-02-14 |
Курна, Инк. |
Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
|
BR112012026227A2
(en)
|
2010-04-13 |
2020-08-04 |
Celldex Therapeutics, Inc. |
human or humanized monoclonal antibody, bispecific molecule, expression vector, transformed cell, composition, and, uses of an antibody
|
WO2011130716A2
(en)
|
2010-04-16 |
2011-10-20 |
Access Pharmaceuticals, Inc. |
A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers
|
KR20220008383A
(en)
|
2010-04-23 |
2022-01-20 |
애로우헤드 파마슈티컬스 인코포레이티드 |
ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
|
WO2011139917A1
(en)
|
2010-04-29 |
2011-11-10 |
Isis Pharmaceuticals, Inc. |
Modulation of transthyretin expression
|
MA34291B1
(en)
|
2010-05-03 |
2013-06-01 |
Genentech Inc |
COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING A TUMOR
|
CN107988228B
(en)
|
2010-05-03 |
2022-01-25 |
库尔纳公司 |
Treatment of Sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to Sirtuin (SIRT)
|
WO2011140151A1
(en)
|
2010-05-04 |
2011-11-10 |
Dyax Corp. |
Antibodies against epidermal growth factor receptor (egfr)
|
CN102958924B
(en)
|
2010-05-05 |
2017-06-27 |
伊利诺伊大学评议会 |
Treat the Compounds and methods for of encephalopathic disease
|
ES2949159T3
(en)
|
2010-05-06 |
2023-09-26 |
Novartis Ag |
Compositions and methods of use for low-density lipoprotein-related protein 6 (LRP6) therapeutic antibodies
|
KR20130066631A
(en)
|
2010-05-06 |
2013-06-20 |
노파르티스 아게 |
Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
|
JP5866106B2
(en)
|
2010-05-12 |
2016-02-17 |
コロンビア ユニヴァーシティ |
Method for producing enteroendocrine cells that produce and secrete insulin
|
TWI531370B
(en)
|
2010-05-14 |
2016-05-01 |
可娜公司 |
Treatment of par4 related diseases by inhibition of natural antisense transcript to par4
|
US8895528B2
(en)
|
2010-05-26 |
2014-11-25 |
Curna, Inc. |
Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
|
CN107441480A
(en)
|
2010-06-30 |
2017-12-08 |
卡姆普根有限公司 |
Polypeptide and its purposes as the medicine for treating multiple sclerosis, rheumatoid arthritis and other autoimmune disorders
|
WO2016030888A1
(en)
|
2014-08-26 |
2016-03-03 |
Compugen Ltd. |
Polypeptides and uses thereof as a drug for treatment of autoimmune disorders
|
CN103068982B
(en)
|
2010-07-14 |
2017-06-09 |
库尔纳公司 |
DLG relevant diseases are treated by suppressing the natural antisense transcript of the big homologue of plate-like (DLG)
|
GB201012420D0
(en)
|
2010-07-23 |
2010-09-08 |
Univ Erasmus Medical Ct |
Foetal heamoglobin inhibitor
|
WO2012022734A2
(en)
|
2010-08-16 |
2012-02-23 |
Medimmune Limited |
Anti-icam-1 antibodies and methods of use
|
CU24094B1
(en)
|
2010-08-20 |
2015-04-29 |
Novartis Ag |
ANTIBODIES FOR THE RECEIVER 3 OF THE EPIDERMAL GROWTH FACTOR (HER3)
|
US9114135B2
(en)
|
2010-08-24 |
2015-08-25 |
Sgc Pharma Inc. |
Salt compound
|
WO2012035518A1
(en)
|
2010-09-17 |
2012-03-22 |
Compugen Ltd. |
Compositions and methods for treatment of drug resistant multiple myeloma
|
EP2621514B1
(en)
|
2010-09-28 |
2016-09-21 |
KAHR Medical (2005) Ltd |
Compositions and methods for treatment of hematological malignancies
|
US9228023B2
(en)
|
2010-10-01 |
2016-01-05 |
Oxford Biotherapeutics Ltd. |
Anti-ROR1 antibodies and methods of use for treatment of cancer
|
CN103154037A
(en)
|
2010-10-05 |
2013-06-12 |
诺瓦提斯公司 |
Anti-IL 12 Rbeta 1 antibodies and their use in treating autoimmune and inflammatory disorders
|
WO2012047968A2
(en)
|
2010-10-05 |
2012-04-12 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
EP2625274B1
(en)
|
2010-10-06 |
2017-07-19 |
CuRNA, Inc. |
Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4
|
CA2815212A1
(en)
|
2010-10-22 |
2012-04-26 |
Curna, Inc. |
Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
|
JP6073795B2
(en)
|
2010-10-27 |
2017-02-01 |
カッパーアールエヌエー,インコーポレイテッド |
Treatment of IFRD1-related diseases by inhibition of natural antisense transcripts to interferon-related developmental regulator 1 (IFRD1)
|
WO2012061811A2
(en)
|
2010-11-05 |
2012-05-10 |
Fibrogen, Inc. |
Treatment method for lung remodeling diseases
|
CN103459599B
(en)
|
2010-11-23 |
2017-06-16 |
库尔纳公司 |
NANOG relevant diseases are treated by suppressing the natural antisense transcript of NANOG
|
EP2643353A1
(en)
|
2010-11-24 |
2013-10-02 |
Novartis AG |
Multispecific molecules
|
WO2012106508A1
(en)
|
2011-02-02 |
2012-08-09 |
Pfizer Inc. |
Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (ctgf)
|
WO2012109495A1
(en)
|
2011-02-09 |
2012-08-16 |
Metabolic Solutions Development Company, Llc |
Cellular targets of thiazolidinediones
|
WO2012119989A2
(en)
|
2011-03-04 |
2012-09-13 |
Oryzon Genomics, S.A. |
Methods and antibodies for the diagnosis and treatment of cancer
|
EP2683410A2
(en)
|
2011-03-08 |
2014-01-15 |
Access Pharmaceuticals, Inc. |
Targeted nanocarrier systems for delivery of actives across biological membranes
|
HUE036172T2
(en)
|
2011-04-01 |
2018-06-28 |
Immunogen Inc |
Methods for increasing efficacy of folr1 cancer therapy
|
AU2012242642A1
(en)
|
2011-04-13 |
2013-05-02 |
Ionis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
WO2012140627A1
(en)
|
2011-04-15 |
2012-10-18 |
Compugen Ltd. |
Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
|
JP6188686B2
(en)
|
2011-06-09 |
2017-08-30 |
カッパーアールエヌエー,インコーポレイテッド |
Treatment of FXN-related diseases by inhibition of natural antisense transcripts to frataxin (FXN)
|
CN103597074A
(en)
|
2011-06-16 |
2014-02-19 |
Isis制药公司 |
Antisense modulation of fibroblast growth factor receptor 4 expression
|
PE20140756A1
(en)
|
2011-06-28 |
2014-07-04 |
Oxford Biotherapeutics Ltd |
ANTIBODIES THAT JOIN BST1
|
EP3357511B1
(en)
|
2011-06-30 |
2020-05-13 |
Genzyme Corporation |
Inhibitors of t-cell activation
|
AU2012277376B2
(en)
|
2011-06-30 |
2016-11-24 |
Compugen Ltd. |
Polypeptides and uses thereof for treatment of autoimmune disorders and infection
|
ES2692519T3
(en)
|
2011-07-01 |
2018-12-04 |
Novartis Ag |
Method to treat metabolic disorders
|
WO2013010955A1
(en)
|
2011-07-15 |
2013-01-24 |
Morphosys Ag |
Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
|
EP2734232B1
(en)
|
2011-07-19 |
2017-11-01 |
Philogen S.p.A. |
Sequential anti-ctla4 and targeted il-2 therapy
|
EP2736928B1
(en)
|
2011-07-28 |
2019-01-09 |
i2 Pharmaceuticals, Inc. |
Sur-binding proteins against erbb3
|
WO2013030778A2
(en)
|
2011-09-02 |
2013-03-07 |
Novartis Ag |
Organic compositions to treat hsf1-related diseases
|
UY34317A
(en)
|
2011-09-12 |
2013-02-28 |
Genzyme Corp |
T cell antireceptor antibody (alpha) / ß
|
CN103814132B
(en)
|
2011-09-20 |
2018-06-05 |
苏州瑞博生物技术有限公司 |
The antisense of GCGR expression is adjusted
|
US20130071403A1
(en)
|
2011-09-20 |
2013-03-21 |
Vical Incorporated |
Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
|
US20130085139A1
(en)
|
2011-10-04 |
2013-04-04 |
Royal Holloway And Bedford New College |
Oligomers
|
CN103906838A
(en)
|
2011-10-25 |
2014-07-02 |
Isis制药公司 |
Antisense modulation of GCCR expression
|
KR102020491B1
(en)
|
2011-10-28 |
2019-09-10 |
온코세라피 사이언스 가부시키가이샤 |
Topk peptides and vaccines including the same
|
EP2788382A2
(en)
|
2011-12-05 |
2014-10-15 |
Novartis AG |
Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
|
CN104159924B
(en)
|
2011-12-05 |
2018-03-16 |
诺华股份有限公司 |
The antibody of EGF-R ELISA 3 (HER3)
|
EP2793940B1
(en)
|
2011-12-22 |
2018-11-14 |
i2 Pharmaceuticals, Inc. |
Surrogate binding proteins
|
JP2015502397A
(en)
|
2011-12-23 |
2015-01-22 |
ファイザー・インク |
Engineered antibody constant regions for site-specific conjugation, and methods and uses therefor
|
US10023862B2
(en)
|
2012-01-09 |
2018-07-17 |
Arrowhead Pharmaceuticals, Inc. |
Organic compositions to treat beta-catenin-related diseases
|
AU2013216320A1
(en)
|
2012-02-01 |
2014-04-03 |
Compugen Ltd. |
C10RF32 antibodies, and uses thereof for treatment of cancer
|
MX350539B
(en)
|
2012-02-13 |
2017-09-08 |
Bristol Myers Squibb Co |
Enediyne compounds, conjugates thereof, and uses and methods therefor.
|
US20150031750A1
(en)
|
2012-03-15 |
2015-01-29 |
The Scripps Research Institute |
Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
|
KR102081046B1
(en)
|
2012-03-16 |
2020-02-25 |
메르크 파텐트 게엠베하 |
Aminoacid lipids
|
JP6527331B2
(en)
|
2012-03-16 |
2019-06-05 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
Target-directed amino acid lipid
|
US20150079100A1
(en)
|
2012-03-23 |
2015-03-19 |
Bristol-Myers Squibb Company |
Methods of treatments using ctla-4 antibodies
|
US9181572B2
(en)
|
2012-04-20 |
2015-11-10 |
Abbvie, Inc. |
Methods to modulate lysine variant distribution
|
WO2013167153A1
(en)
|
2012-05-09 |
2013-11-14 |
Ganymed Pharmaceuticals Ag |
Antibodies useful in cancer diagnosis
|
KR102238317B1
(en)
|
2012-05-17 |
2021-04-12 |
익스텐드 바이오사이언시즈, 인크. |
Carriers for improved drug delivery
|
WO2013176754A1
(en)
|
2012-05-24 |
2013-11-28 |
Abbvie Inc. |
Novel purification of antibodies using hydrophobic interaction chromatography
|
ES2703540T3
(en)
|
2012-06-04 |
2019-03-11 |
Novartis Ag |
Site-specific marking methods and molecules produced in this way
|
WO2014039983A1
(en)
|
2012-09-07 |
2014-03-13 |
The Trustees Of Dartmouth College |
Vista modulators for diagnosis and treatment of cancer
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
AR091649A1
(en)
|
2012-07-02 |
2015-02-18 |
Bristol Myers Squibb Co |
OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES
|
NZ726258A
(en)
|
2012-08-31 |
2019-07-26 |
Immunogen Inc |
Antibodies and uses thereof to detect folate receptor 1
|
WO2014041179A1
(en)
|
2012-09-17 |
2014-03-20 |
Chemedest Ltd. |
Treatment of peripheral neuropathy using gfr(alpha)3 type receptor agonists
|
WO2014055493A1
(en)
|
2012-10-02 |
2014-04-10 |
Cerulean Pharma Inc. |
Methods and systems for polymer precipitation and generation of particles
|
CA2889181C
(en)
|
2012-10-22 |
2021-12-07 |
Fountain Biopharma Inc. |
Antibodies to interleukin-6 and uses thereof
|
JP2016509572A
(en)
|
2012-11-05 |
2016-03-31 |
プロナイ セラピューティクス インコーポレイテッド |
Methods of using biomarkers for the treatment of cancer by modulating BCL2 expression
|
MX2015005874A
(en)
|
2012-11-09 |
2015-09-10 |
Pfizer |
Platelet-derived growth factor b specific antibodies and compositions and uses thereof.
|
SI2935320T1
(en)
|
2012-12-18 |
2019-12-31 |
Novartis Ag |
Stabilized insulin-like growth factor polypeptides
|
CN105143271A
(en)
|
2013-02-08 |
2015-12-09 |
Irm责任有限公司 |
Specific sites for modifying antibodies to make immunoconjugates
|
WO2014124258A2
(en)
|
2013-02-08 |
2014-08-14 |
Irm Llc |
Specific sites for modifying antibodies to make immunoconjugates
|
SI2953969T1
(en)
|
2013-02-08 |
2020-01-31 |
Novartis Ag |
Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
|
RS56169B1
(en)
|
2013-02-14 |
2017-11-30 |
Bristol Myers Squibb Co |
Tubulysin compounds, methods of making and use
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
SG11201504260UA
(en)
|
2013-03-14 |
2015-10-29 |
Abbvie Inc |
Low acidic species compositions and methods for producing and using the same
|
EP2970479B1
(en)
|
2013-03-14 |
2019-04-24 |
Novartis AG |
Antibodies against notch 3
|
WO2014159554A1
(en)
|
2013-03-14 |
2014-10-02 |
Abbvie Inc. |
Low acidic species compositions and methods for producing the same using displacement chromatography
|
WO2014152497A2
(en)
|
2013-03-15 |
2014-09-25 |
The Trustees Of Columbia University In The City Of New York |
Osteocalcin as a treatment for cognitive disorders
|
CN105007950B
(en)
|
2013-03-15 |
2019-01-15 |
诺华股份有限公司 |
Antibody drug conjugate
|
US9308236B2
(en)
|
2013-03-15 |
2016-04-12 |
Bristol-Myers Squibb Company |
Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
|
CA2918787A1
(en)
|
2013-06-13 |
2014-12-18 |
George Tachas |
Combination therapy
|
EP3013818B1
(en)
|
2013-06-26 |
2021-12-29 |
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
(s)-enantiomer of mepazine as paracaspase (malt1) inhibitor for treating cancer
|
KR102585409B1
(en)
|
2013-08-30 |
2023-10-05 |
이뮤노젠 아이엔씨 |
Antibodies and assays for detection of folate receptor 1
|
US20150197534A1
(en)
|
2013-09-05 |
2015-07-16 |
Sarepta Therapeutics, Inc. |
Antisense-induced exon2 inclusion in acid alpha-glucosidase
|
EP3045917A2
(en)
|
2013-09-13 |
2016-07-20 |
Sierra Jiménez, Angels |
Marker for predicting metastasis of breast cancer
|
WO2015042466A2
(en)
|
2013-09-19 |
2015-03-26 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Compositions and methods for inhibiting jc virus (jcv)
|
WO2015050959A1
(en)
|
2013-10-01 |
2015-04-09 |
Yale University |
Anti-kit antibodies and methods of use thereof
|
CN105792839A
(en)
|
2013-10-02 |
2016-07-20 |
诺华股份有限公司 |
Insulin-like growth factor mimetics for use in therapy
|
PT3055331T
(en)
|
2013-10-11 |
2021-04-05 |
Oxford Bio Therapeutics Ltd |
Conjugated antibodies against ly75 for the treatment of cancer
|
SG10201810298VA
(en)
|
2013-11-13 |
2018-12-28 |
Pfizer |
Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
|
EP3574924B1
(en)
|
2013-11-19 |
2021-01-06 |
Purdue Research Foundation |
Patient selection method for inflammation
|
UY35874A
(en)
|
2013-12-12 |
2015-07-31 |
Novartis Ag |
A PROCESS FOR THE PREPARATION OF A COMPOSITION OF PEGILATED PROTEINS
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
PL3712174T3
(en)
|
2013-12-24 |
2022-07-04 |
Janssen Pharmaceutica Nv |
Anti-vista antibodies and fragments
|
WO2015109212A1
(en)
|
2014-01-17 |
2015-07-23 |
Pfizer Inc. |
Anti-il-2 antibodies and compositions and uses thereof
|
WO2015116902A1
(en)
|
2014-01-31 |
2015-08-06 |
Genentech, Inc. |
G-protein coupled receptors in hedgehog signaling
|
WO2015120075A2
(en)
|
2014-02-04 |
2015-08-13 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
KR20160125515A
(en)
|
2014-03-12 |
2016-10-31 |
노파르티스 아게 |
Specific sites for modifying antibodies to make immunoconjugates
|
WO2015171918A2
(en)
|
2014-05-07 |
2015-11-12 |
Louisiana State University And Agricultural And Mechanical College |
Compositions and uses for treatment thereof
|
GB201408623D0
(en)
|
2014-05-15 |
2014-07-02 |
Santaris Pharma As |
Oligomers and oligomer conjugates
|
EA037006B1
(en)
|
2014-06-06 |
2021-01-26 |
Бристол-Майерс Сквибб Компани |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
|
MX2016016310A
(en)
|
2014-06-11 |
2017-10-20 |
A Green Kathy |
Use of vista agonists and antagonists to suppress or enhance humoral immunity.
|
EP3161001A2
(en)
|
2014-06-25 |
2017-05-03 |
Novartis AG |
Antibodies specific for il-17a fused to hyaluronan binding peptide tags
|
CA2985344A1
(en)
|
2014-06-26 |
2015-12-30 |
The Trustees Of Columbia University In The City Of New York |
Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells
|
WO2016004197A1
(en)
|
2014-07-03 |
2016-01-07 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using cobalt
|
US20160185848A1
(en)
|
2014-07-09 |
2016-06-30 |
Abbvie Inc. |
Methods for modulating the glycosylation profile of recombinant proteins using sugars
|
ES2729202T3
(en)
|
2014-07-16 |
2019-10-30 |
Dana Farber Cancer Inst Inc Et Al |
Inhibition of HER3 in low grade serous ovarian cancers
|
WO2016020791A1
(en)
|
2014-08-05 |
2016-02-11 |
Novartis Ag |
Ckit antibody drug conjugates
|
WO2016025331A1
(en)
|
2014-08-11 |
2016-02-18 |
University Of Massachusetts |
Anti-ospa antibodies and methods of use
|
TN2016000577A1
(en)
|
2014-08-12 |
2018-04-04 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates
|
WO2016033424A1
(en)
|
2014-08-29 |
2016-03-03 |
Genzyme Corporation |
Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
|
EP2993174A1
(en)
|
2014-09-08 |
2016-03-09 |
Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH |
Pyrazolopyridine derivatives and their use in therapy
|
US9732119B2
(en)
|
2014-10-10 |
2017-08-15 |
Bristol-Myers Squibb Company |
Immunomodulators
|
WO2016065052A1
(en)
|
2014-10-22 |
2016-04-28 |
Extend Biosciences, Inc. |
Insulin vitamin d conjugates
|
US9789197B2
(en)
|
2014-10-22 |
2017-10-17 |
Extend Biosciences, Inc. |
RNAi vitamin D conjugates
|
WO2016065042A1
(en)
|
2014-10-22 |
2016-04-28 |
Extend Biosciences, Inc. |
Therapeutic vitamin d conjugates
|
US10647687B2
(en)
|
2014-11-10 |
2020-05-12 |
Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) |
Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death
|
US10077287B2
(en)
|
2014-11-10 |
2018-09-18 |
Bristol-Myers Squibb Company |
Tubulysin analogs and methods of making and use
|
US9856292B2
(en)
|
2014-11-14 |
2018-01-02 |
Bristol-Myers Squibb Company |
Immunomodulators
|
JP6831783B2
(en)
|
2014-11-14 |
2021-02-17 |
ノバルティス アーゲー |
Antibody drug conjugate
|
WO2016081728A1
(en)
|
2014-11-19 |
2016-05-26 |
The Trustees Of Columbia University In The City Of New York |
Osteocalcin as a treatment for frailty associated with aging
|
EP3221346B1
(en)
|
2014-11-21 |
2020-09-02 |
Bristol-Myers Squibb Company |
Antibodies comprising modified heavy constant regions
|
RS60631B1
(en)
|
2014-11-21 |
2020-09-30 |
Bristol Myers Squibb Co |
Antibodies against cd73 and uses thereof
|
EP3223866B1
(en)
|
2014-11-25 |
2023-03-08 |
Bristol-Myers Squibb Company |
Methods and compositions for 18f-radiolabeling of the fibronectin type (iii) domain
|
EP3224277B1
(en)
|
2014-11-25 |
2020-08-26 |
Bristol-Myers Squibb Company |
Novel pd-l1 binding polypeptides for imaging
|
EP3227341A1
(en)
|
2014-12-02 |
2017-10-11 |
CeMM - Forschungszentrum für Molekulare Medizin GmbH |
Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies
|
EP3226900A4
(en)
|
2014-12-05 |
2018-09-19 |
Immunext, Inc. |
Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators
|
JP6847835B2
(en)
|
2014-12-12 |
2021-03-24 |
ザ ジェネラル ホスピタル コーポレイション |
Treatment of breast cancer brain metastases
|
US9861680B2
(en)
|
2014-12-18 |
2018-01-09 |
Bristol-Myers Squibb Company |
Immunomodulators
|
US9944678B2
(en)
|
2014-12-19 |
2018-04-17 |
Bristol-Myers Squibb Company |
Immunomodulators
|
PT3233912T
(en)
|
2014-12-19 |
2021-08-09 |
Regenesance B V |
Antibodies that bind human c6 and uses thereof
|
TWI708786B
(en)
|
2014-12-23 |
2020-11-01 |
美商必治妥美雅史谷比公司 |
Antibodies to tigit
|
WO2016115201A1
(en)
|
2015-01-14 |
2016-07-21 |
Bristol-Myers Squibb Company |
Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and using
|
TW201632202A
(en)
|
2015-01-30 |
2016-09-16 |
諾華公司 |
Treatment of breast cancer
|
US20160222060A1
(en)
|
2015-02-04 |
2016-08-04 |
Bristol-Myers Squibb Company |
Immunomodulators
|
WO2016144773A1
(en)
|
2015-03-06 |
2016-09-15 |
Abbvie Inc. |
Arabinosylated glycoproteins
|
EP3268037B1
(en)
|
2015-03-09 |
2022-08-31 |
Celldex Therapeutics, Inc. |
Cd27 agonists
|
MA41795A
(en)
|
2015-03-18 |
2018-01-23 |
Sarepta Therapeutics Inc |
EXCLUSION OF AN EXON INDUCED BY ANTISENSE COMPOUNDS IN MYOSTATIN
|
US9809625B2
(en)
|
2015-03-18 |
2017-11-07 |
Bristol-Myers Squibb Company |
Immunomodulators
|
WO2016162405A1
(en)
|
2015-04-10 |
2016-10-13 |
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Pyrone derivatives for use as antiviral agents
|
EP4014985A1
(en)
|
2015-05-01 |
2022-06-22 |
Allysta Pharmaceuticals, Inc. |
Adiponectin peptidomimetics for treating ocular disorders
|
WO2016187068A1
(en)
|
2015-05-15 |
2016-11-24 |
The General Hospital Corporation |
Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
|
US10568852B2
(en)
|
2015-05-22 |
2020-02-25 |
Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) |
Combination compositions and their use in methods for treating obesity and obesity-related disorders
|
KR20180010217A
(en)
*
|
2015-05-26 |
2018-01-30 |
더 제너럴 하스피탈 코포레이션 |
Liposome nano-constructs, and methods for making and using the same
|
CA2987410A1
(en)
|
2015-05-29 |
2016-12-08 |
Bristol-Myers Squibb Company |
Antibodies against ox40 and uses thereof
|
EP3851531A1
(en)
|
2015-06-01 |
2021-07-21 |
Sarepta Therapeutics, Inc. |
Antisense-induced exon exclusion in type vii collagen
|
WO2016203432A1
(en)
|
2015-06-17 |
2016-12-22 |
Novartis Ag |
Antibody drug conjugates
|
JP7026509B2
(en)
|
2015-06-24 |
2022-02-28 |
ヤンセン ファーマシューティカ エヌブイ |
Anti-VISTA antibody and fragment
|
AU2016285920A1
(en)
|
2015-06-29 |
2018-02-01 |
Bristol-Myers Squibb Company |
Antibodies to CD40 with enhanced agonist activity
|
CA2991980A1
(en)
|
2015-07-13 |
2017-01-19 |
Compugen Ltd. |
Hide1 compositions and methods
|
CA3025896A1
(en)
|
2015-07-23 |
2017-01-26 |
The Regents Of The University Of California |
Antibodies to coagulation factor xia and uses thereof
|
US9862760B2
(en)
|
2015-09-16 |
2018-01-09 |
Novartis Ag |
Polyomavirus neutralizing antibodies
|
EP3349796A4
(en)
|
2015-09-17 |
2019-05-29 |
ImmunoGen, Inc. |
Therapeutic combinations comprising anti-folr1 immunoconjugates
|
US10954300B2
(en)
|
2015-09-28 |
2021-03-23 |
The Trustees Of Columbia University In The City Of New York |
Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma
|
RU2638457C2
(en)
|
2015-09-28 |
2017-12-13 |
Общество С Ограниченной Ответственностью "Онкомакс" |
Antibodies specifically binding type 1 receptor of fibroblast growth factor, antibodies application for oncological disease treatment, method for antibodies production
|
WO2017059132A1
(en)
|
2015-09-29 |
2017-04-06 |
The General Hospital Corporation |
Methods of treating and diagnosing disease using biomarkers for bcg therapy
|
JP2018530560A
(en)
|
2015-10-09 |
2018-10-18 |
サレプタ セラピューティクス, インコーポレイテッド |
Compositions and methods for the treatment of Duchenne muscular dystrophy and related disorders
|
KR20180064541A
(en)
|
2015-10-23 |
2018-06-14 |
화이자 인코포레이티드 |
Anti-IL-2 antibodies and compositions and uses thereof
|
MA44334A
(en)
|
2015-10-29 |
2018-09-05 |
Novartis Ag |
ANTIBODY CONJUGATES INCLUDING A TOLL-TYPE RECEPTOR AGONIST
|
EP3370734B1
(en)
|
2015-11-05 |
2023-01-04 |
Children's Hospital Los Angeles |
Antisense oligo for use in treating acute myeloid leukemia
|
CN106699889A
(en)
|
2015-11-18 |
2017-05-24 |
礼进生物医药科技(上海)有限公司 |
PD-1 resisting antibody and treatment application thereof
|
AU2016356780A1
(en)
|
2015-11-19 |
2018-06-28 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
|
CA3006759A1
(en)
|
2015-11-30 |
2017-06-08 |
The Regents Of The University Of California |
Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
|
WO2017095875A1
(en)
|
2015-11-30 |
2017-06-08 |
Bristol-Myers Squibb Company |
Anti human ip-10 antibodies and their uses
|
EP3851457A1
(en)
|
2016-01-21 |
2021-07-21 |
Novartis AG |
Multispecific molecules targeting cll-1
|
CA3019952A1
(en)
|
2016-02-04 |
2017-08-10 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
CN116920085A
(en)
|
2016-02-12 |
2023-10-24 |
詹森药业有限公司 |
anti-VISTA (B7H 5) antibodies
|
RU2018131123A
(en)
|
2016-02-17 |
2020-03-17 |
Новартис Аг |
ANTIBODIES TO TGF-BETA2
|
EA201891983A8
(en)
|
2016-03-04 |
2020-05-28 |
Бристол-Майерс Сквибб Компани |
COMBINED THERAPY BY ANTIBODIES TO CD73
|
US10143746B2
(en)
|
2016-03-04 |
2018-12-04 |
Bristol-Myers Squibb Company |
Immunomodulators
|
SG11201807677YA
(en)
|
2016-03-04 |
2018-10-30 |
Univ Rockefeller |
Antibodies to cd40 with enhanced agonist activity
|
US10358463B2
(en)
|
2016-04-05 |
2019-07-23 |
Bristol-Myers Squibb Company |
Immunomodulators
|
RU2021111187A
(en)
|
2016-04-15 |
2021-04-29 |
Янссен Фармасьютикалз, Инк. |
ANTIBODIES AGAINST HUMAN VISTA AND THEIR APPLICATION
|
KR102522059B1
(en)
|
2016-04-18 |
2023-04-14 |
사렙타 쎄러퓨틱스 인코퍼레이티드 |
Antisense oligomers and methods of their use to treat diseases associated with the acid alpha-glucosidase gene
|
MA44723A
(en)
|
2016-04-18 |
2019-02-27 |
Celldex Therapeutics Inc |
HUMAN CD40 BINDING AGONIST ANTIBODIES AND THEIR USES
|
SI3445850T1
(en)
|
2016-04-22 |
2021-12-31 |
BioNTech SE |
Methods for providing single-stranded rna
|
WO2017201111A1
(en)
|
2016-05-19 |
2017-11-23 |
Bristol-Myers Squibb Company |
Pet-imaging immunomodulators
|
US10994033B2
(en)
|
2016-06-01 |
2021-05-04 |
Bristol-Myers Squibb Company |
Imaging methods using 18F-radiolabeled biologics
|
CN109562195A
(en)
|
2016-06-01 |
2019-04-02 |
百时美施贵宝公司 |
PET imaging is carried out with PD-L1 combination polypeptide
|
US20180002417A1
(en)
|
2016-06-15 |
2018-01-04 |
Celimmune Llc |
Methods and Compositions for the Treatment of Celiac Disease, Non-Celiac Gluten Sensitivity, and Refractory Celiac Disease
|
JP7027401B2
(en)
|
2016-07-14 |
2022-03-01 |
ブリストル-マイヤーズ スクイブ カンパニー |
Antibodies to TIM3 and its use
|
KR102493853B1
(en)
|
2016-08-19 |
2023-01-30 |
브리스톨-마이어스 스큅 컴퍼니 |
Seco-cyclopropapyrroloindole compounds, antibody-drug conjugates thereof, and methods of manufacture and use
|
WO2018044970A1
(en)
|
2016-08-31 |
2018-03-08 |
University Of Rochester |
Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof
|
EP3305781A1
(en)
|
2016-10-07 |
2018-04-11 |
Deutsches Krebsforschungszentrum |
Chemical substances which inhibit the enzymatic activity of human kallikrein-related peptidase 6 (klk6)
|
WO2018071822A2
(en)
|
2016-10-13 |
2018-04-19 |
Massachusetts Institute Of Technology |
Antibodies that bind zika virus envelope protein and uses thereof
|
CN110267971B
(en)
|
2016-11-07 |
2023-12-19 |
百时美施贵宝公司 |
Immunomodulators
|
WO2018085836A1
(en)
|
2016-11-07 |
2018-05-11 |
Colorado State University Research Foundation |
Anti-hiv peptides
|
US11434301B2
(en)
|
2016-11-11 |
2022-09-06 |
The Regents Of The University Of California |
Anti-CD46 antibodies and methods of use
|
US11702458B2
(en)
|
2017-01-05 |
2023-07-18 |
Kahr Medical Ltd. |
PD1-41BBL fusion protein and methods of use thereof
|
SI3565828T1
(en)
|
2017-01-05 |
2022-04-29 |
Kahr Medical Ltd. |
A sirp1 alpha-41bbl fusion protein and methods of use thereof
|
US11377497B2
(en)
|
2017-01-23 |
2022-07-05 |
Suzhou Alphamab Co., Ltd. |
PD-L1 binding polypeptide or composite
|
JOP20190187A1
(en)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
Anti-ccr7 antibody drug conjugates
|
EP3583124A1
(en)
|
2017-02-17 |
2019-12-25 |
Bristol-Myers Squibb Company |
Antibodies to alpha-synuclein and uses thereof
|
GB201703876D0
(en)
|
2017-03-10 |
2017-04-26 |
Berlin-Chemie Ag |
Pharmaceutical combinations
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
TWI788340B
(en)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
Anti-icos agonist antibodies and uses thereof
|
AR111651A1
(en)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
CONJUGATES OF ANTIBODIES THAT INCLUDE TOLL TYPE RECEIVER AGONISTS AND COMBINATION THERAPIES
|
US10994025B2
(en)
|
2017-05-12 |
2021-05-04 |
Massachusetts Institute Of Technology |
Argonaute protein-double stranded RNA complexes and uses related thereto
|
CN111094335B
(en)
|
2017-05-15 |
2022-08-23 |
罗切斯特大学 |
Broadly neutralizing anti-influenza monoclonal antibodies and uses thereof
|
KR20220167342A
(en)
|
2017-05-25 |
2022-12-20 |
브리스톨-마이어스 스큅 컴퍼니 |
Antibodies comprising modified heavy constant regions
|
JP2020523035A
(en)
|
2017-06-07 |
2020-08-06 |
エーディーアールエックス, インコーポレイテッド |
Tau aggregation inhibitor
|
KR20200020858A
(en)
|
2017-06-23 |
2020-02-26 |
브리스톨-마이어스 스큅 컴퍼니 |
Immunomodulators Acting as Antagonists of PD-1
|
WO2018233333A1
(en)
|
2017-06-23 |
2018-12-27 |
苏州博聚华生物医药科技有限公司 |
Monoclonal antibody of targeted human tumor stem cells and application of monoclonal antibody
|
US11453701B2
(en)
|
2017-08-18 |
2022-09-27 |
Adrx, Inc. |
Tau aggregation peptide inhibitors
|
MX2020002351A
(en)
|
2017-08-28 |
2021-02-26 |
Shanghai Yile Biotechnology Co Ltd |
Polypeptide and antibody bound to polypeptide.
|
US11492375B2
(en)
|
2017-10-03 |
2022-11-08 |
Bristol-Myers Squibb Company |
Cyclic peptide immunomodulators
|
WO2019075090A1
(en)
|
2017-10-10 |
2019-04-18 |
Tilos Therapeutics, Inc. |
Anti-lap antibodies and uses thereof
|
WO2019079637A2
(en)
|
2017-10-18 |
2019-04-25 |
Sarepta Therapeutics, Inc. |
Antisense oligomer compounds
|
EP3700938A1
(en)
|
2017-10-26 |
2020-09-02 |
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. |
Novel recombinant fusion proteins, preparation and use thereof
|
WO2019089921A1
(en)
|
2017-11-01 |
2019-05-09 |
Bristol-Myers Squibb Company |
Immunostimulatory agonistic antibodies for use in treating cancer
|
US11673963B2
(en)
|
2017-11-02 |
2023-06-13 |
Oxford Biotherapeutics Ltd |
CRTAM antibodies and methods of treating cancer
|
CA3083363A1
(en)
|
2017-12-01 |
2019-06-06 |
Novartis Ag |
Polyomavirus neutralizing antibodies
|
KR20200092328A
(en)
|
2017-12-01 |
2020-08-03 |
화이자 인코포레이티드 |
Anti-CXCR5 antibodies and compositions and uses thereof
|
CN111655728B
(en)
|
2017-12-20 |
2022-02-22 |
和铂医药(上海)有限责任公司 |
Antibodies that bind CTLA-4 and uses thereof
|
SG11202004971YA
(en)
|
2017-12-21 |
2020-06-29 |
Gliapharm Sa |
Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
|
SG11202004966PA
(en)
|
2017-12-21 |
2020-06-29 |
Gliapharm Sa |
Compositions and methods of treatment for neurological disorders comprising a dementia
|
EP3732198A1
(en)
|
2017-12-27 |
2020-11-04 |
Bristol-Myers Squibb Company |
Anti-cd40 antibodies and uses thereof
|
JP7358361B2
(en)
|
2018-01-12 |
2023-10-10 |
ブリストル-マイヤーズ スクイブ カンパニー |
Antibodies against TIM3 and their uses
|
US20210363172A1
(en)
|
2018-03-15 |
2021-11-25 |
Biontech Rna Pharmaceuticals Gmbh |
5'-cap-trinucleotide- or higher oligonucleotide compounds and their use in stabilizing rna, expressing proteins in therapy
|
TW202003565A
(en)
|
2018-03-23 |
2020-01-16 |
美商必治妥美雅史谷比公司 |
Antibodies against MICA and/or MICB and uses thereof
|
EP3777889A4
(en)
|
2018-03-26 |
2022-01-26 |
Shanghai Yile Biotechnology Co., Ltd. |
Use of probdnf regulator in b cell-related diseases
|
AU2019242451A1
(en)
|
2018-03-29 |
2020-11-12 |
Pfizer Inc. |
LFA3 variants and compositions and uses thereof
|
US11155618B2
(en)
|
2018-04-02 |
2021-10-26 |
Bristol-Myers Squibb Company |
Anti-TREM-1 antibodies and uses thereof
|
US20210155959A1
(en)
|
2018-04-06 |
2021-05-27 |
Children's Medical Center Corporation |
Compositions and methods for somatic cell reprogramming and modulating imprinting
|
CA3096674A1
(en)
|
2018-04-12 |
2019-10-17 |
Bristol-Myers Squibb Company |
Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody
|
KR20210011919A
(en)
|
2018-04-17 |
2021-02-02 |
셀덱스 쎄라퓨틱스, 인크. |
Anti-CD27 antibody and anti-PD-L1 antibody and bispecific construct
|
WO2019202160A2
(en)
|
2018-04-20 |
2019-10-24 |
Iomx Therapeutics Ag |
A 5-thiazolecarboxamide kinase inhibitor and uses thereof
|
CA3096703A1
(en)
|
2018-05-03 |
2019-11-07 |
University Of Rochester |
Anti-influenza neuraminidase monoclonal antibodies and uses thereof
|
EP3801766A1
(en)
|
2018-05-31 |
2021-04-14 |
Novartis AG |
Hepatitis b antibodies
|
AU2019277029C1
(en)
|
2018-06-01 |
2024-01-04 |
Novartis Ag |
Binding molecules against BCMA and uses thereof
|
GB201809746D0
(en)
|
2018-06-14 |
2018-08-01 |
Berlin Chemie Ag |
Pharmaceutical combinations
|
CA3111339A1
(en)
|
2018-07-10 |
2020-01-16 |
Rush University Medical Center |
Use of immunomodulators to control infection and stimulate healing in normal and diabetic wounds
|
MX2021000263A
(en)
|
2018-07-11 |
2021-05-12 |
Kahr Medical Ltd |
SIRPalpha-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF.
|
JP7193058B2
(en)
|
2018-08-08 |
2022-12-20 |
イミューンオンコ バイオファーマシューティカルズ (シャンハイ) インコーポレイテッド |
Recombinant bifunctional protein targeting CD47 and HER2
|
CN112823167A
(en)
|
2018-09-07 |
2021-05-18 |
辉瑞大药厂 |
Anti-alphavbeta 8 antibodies and compositions and uses thereof
|
WO2020053742A2
(en)
|
2018-09-10 |
2020-03-19 |
Novartis Ag |
Anti-hla-hbv peptide antibodies
|
JP2022504839A
(en)
|
2018-10-10 |
2022-01-13 |
ティロス・セラピューティクス・インコーポレイテッド |
Anti-LAP antibody mutants and their use
|
EP3643713A1
(en)
|
2018-10-23 |
2020-04-29 |
iOmx Therapeutics AG |
Heterocyclic kinase inhibitors and uses thereof
|
US20220024944A1
(en)
|
2018-10-23 |
2022-01-27 |
Myelopro Diagnostics And Research Gmbh |
Compounds targeting mutant calreticulin
|
US11827670B2
(en)
|
2018-11-09 |
2023-11-28 |
University Of Massachusetts |
Anti-CfaE antibodies and methods of use
|
PE20211284A1
(en)
|
2018-11-16 |
2021-07-19 |
Bristol Myers Squibb Co |
ANTI-NKG2A ANTIBODIES AND USES OF THEM
|
JP2022513653A
(en)
|
2018-11-28 |
2022-02-09 |
ブリストル-マイヤーズ スクイブ カンパニー |
Antibodies containing modified heavy chain constant regions
|
WO2020128863A1
(en)
|
2018-12-19 |
2020-06-25 |
Novartis Ag |
Anti-tnf-alpha antibodies
|
CN113614109A
(en)
|
2018-12-21 |
2021-11-05 |
Ose免疫疗法公司 |
Bifunctional anti-PD-1/IL-7 molecules
|
US20220025050A1
(en)
|
2018-12-21 |
2022-01-27 |
Ose Immunotherapeutics |
Bifunctional molecule directed against human pd-1
|
US20220056135A1
(en)
|
2018-12-21 |
2022-02-24 |
Ose Immunotherapeutics |
Bifunctional anti-pd-1/sirpa molecule
|
DK3883966T3
(en)
|
2018-12-21 |
2023-10-16 |
Ose Immunotherapeutics |
HUMANIZED ANTI-HUMAN PD-1 ANTIBODY
|
BR112021011900A2
(en)
|
2018-12-21 |
2021-09-08 |
Novartis Ag |
ANTIBODIES TO PMEL17 AND CONJUGATES THEREOF
|
WO2020132378A2
(en)
|
2018-12-22 |
2020-06-25 |
Gliapharm Sa |
Compositions and methods of treatment for neurological disorders comprising depression
|
CN109762067B
(en)
|
2019-01-17 |
2020-02-28 |
北京天广实生物技术股份有限公司 |
Antibodies that bind human Claudin18.2 and uses thereof
|
WO2020165374A1
(en)
|
2019-02-14 |
2020-08-20 |
Ose Immunotherapeutics |
Bifunctional molecule comprising il-15ra
|
CN113557228A
(en)
|
2019-03-08 |
2021-10-26 |
阿比蒂斯有限公司 |
Site-specific antibody conjugates and antibody-drug conjugates as specific examples thereof
|
MA55529A
(en)
|
2019-04-03 |
2022-02-09 |
Genzyme Corp |
REDUCED FRAGMENTATION ANTI-ALPHA BETA TCR BINDING POLYPEPTIDES
|
CA3140063A1
(en)
|
2019-05-20 |
2020-11-26 |
Novartis Ag |
Antibody drug conjugates having linkers comprising hydrophilic groups
|
JP2022533233A
(en)
|
2019-05-21 |
2022-07-21 |
ブリストル-マイヤーズ スクイブ カンパニー |
Immunomodulator
|
US20220372137A1
(en)
|
2019-07-03 |
2022-11-24 |
Oxford Biotherapeutics Ltd |
Antibodies and methods of use
|
MX2022000367A
(en)
|
2019-07-11 |
2022-07-13 |
Kahr Medical Ltd |
Heterodimers and methods of use thereof.
|
WO2021011681A1
(en)
|
2019-07-15 |
2021-01-21 |
Bristol-Myers Squibb Company |
Antibodies against human trem-1 and uses thereof
|
EP3999543A1
(en)
|
2019-07-15 |
2022-05-25 |
Bristol-Myers Squibb Company |
Anti-trem-1 antibodies and uses thereof
|
KR20220088868A
(en)
|
2019-10-30 |
2022-06-28 |
브리스톨-마이어스 스큅 컴퍼니 |
immunomodulators
|
WO2021102143A1
(en)
|
2019-11-19 |
2021-05-27 |
Bristol-Myers Squibb Company |
Macrocyclic peptides as pd-l1 inhibitors and immunomodulators for the treatment of cancer and infectious diseases
|
JP2023510737A
(en)
|
2020-01-06 |
2023-03-15 |
ブリストル-マイヤーズ スクイブ カンパニー |
Immunomodulator
|
CN114929714A
(en)
|
2020-01-06 |
2022-08-19 |
百时美施贵宝公司 |
Macrocyclic peptides as PD-L1 inhibitors and immunomodulators for the treatment of cancer and infectious diseases
|
US20230105029A1
(en)
|
2020-02-27 |
2023-04-06 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Antibodies binding il4r and uses thereof
|
WO2021174045A1
(en)
|
2020-02-28 |
2021-09-02 |
Bristol-Myers Squibb Company |
Radiolabeled fibronectin based scaffolds and antibodies and theranostic uses thereof
|
US20230140384A1
(en)
|
2020-03-09 |
2023-05-04 |
Bristol-Myers Squibb Company |
Antibodies to cd40 with enhanced agonist activity
|
US20230183292A1
(en)
|
2020-03-16 |
2023-06-15 |
Bristol-Myers Squibb Company |
Immunomodulators
|
KR20220161407A
(en)
|
2020-03-30 |
2022-12-06 |
브리스톨-마이어스 스큅 컴퍼니 |
immunomodulator
|
CA3170570A1
(en)
|
2020-04-01 |
2021-10-07 |
James J. KOBIE |
Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses
|
US20230272056A1
(en)
|
2020-04-09 |
2023-08-31 |
Merck Sharp & Dohme Llc |
Affinity matured anti-lap antibodies and uses thereof
|
EP3901151A1
(en)
|
2020-04-21 |
2021-10-27 |
iOmx Therapeutics AG |
Halogenated-heteroaryl and other heterocyclic kinase inhibitors, and uses thereof
|
US11634477B2
(en)
|
2020-04-28 |
2023-04-25 |
The Rockefeller University |
Neutralizing anti-SARS-CoV-2 antibodies and methods of use thereof
|
WO2021219731A2
(en)
|
2020-04-28 |
2021-11-04 |
Iomx Therapeutics Ag |
Bicyclic kinase inhibitors and uses thereof
|
US20230181756A1
(en)
|
2020-04-30 |
2023-06-15 |
Novartis Ag |
Ccr7 antibody drug conjugates for treating cancer
|
CN115461363A
(en)
|
2020-05-01 |
2022-12-09 |
诺华股份有限公司 |
Immunoglobulin variants
|
EP4143236A1
(en)
|
2020-05-01 |
2023-03-08 |
Novartis AG |
Engineered immunoglobulins
|
CN115916340A
(en)
|
2020-05-08 |
2023-04-04 |
百时美施贵宝公司 |
Immunomodulator
|
WO2021231732A1
(en)
|
2020-05-15 |
2021-11-18 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
US20230277524A1
(en)
|
2020-05-22 |
2023-09-07 |
Trailhead Biosystems Inc. |
Combination therapy for treatment of viral infections
|
EP4192511A1
(en)
|
2020-08-07 |
2023-06-14 |
Fortis Therapeutics, Inc. |
Immunoconjugates targeting cd46 and methods of use thereof
|
JP2023541403A
(en)
|
2020-09-09 |
2023-10-02 |
ソーシャル・プロフィット・ネットワーク |
Methods and compositions for delivering biotin to mitochondria
|
US20230365627A1
(en)
|
2020-10-02 |
2023-11-16 |
Bristol-Myers Squibb Company |
Macrocyclic peptide boronate immunomodulators
|
JP2023546020A
(en)
|
2020-10-08 |
2023-11-01 |
ブリストル-マイヤーズ スクイブ カンパニー |
Novel dimeric immunomodulator
|
CN116323640A
(en)
|
2020-10-09 |
2023-06-23 |
百时美施贵宝公司 |
Macrocyclic immunomodulators
|
AR123997A1
(en)
|
2020-11-04 |
2023-02-01 |
Univ Rockefeller |
NEUTRALIZING ANTIBODIES AGAINST SARS-CoV-2
|
EP4240494A1
(en)
|
2020-11-06 |
2023-09-13 |
Novartis AG |
Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
|
EP4240765A2
(en)
|
2020-11-06 |
2023-09-13 |
Novartis AG |
Antibody fc variants
|
WO2022097060A1
(en)
|
2020-11-06 |
2022-05-12 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
CN116547305A
(en)
|
2020-11-11 |
2023-08-04 |
生物技术公司 |
Monoclonal antibodies against programmed death-1 proteins and their use in medicine
|
CN114685669A
(en)
|
2020-12-30 |
2022-07-01 |
和铂医药(苏州)有限公司 |
Antibodies that bind TROP2 and uses thereof
|
US20220227844A1
(en)
|
2021-01-15 |
2022-07-21 |
The Rockefeller University |
Neutralizing anti-sars-cov-2 antibodies
|
WO2022204412A1
(en)
|
2021-03-24 |
2022-09-29 |
Bristol-Myers Squibb Company |
Immunomodulators
|
BR112023020303A2
(en)
|
2021-04-09 |
2023-11-14 |
Celldex Therapeutics Inc |
ANTIBODIES AGAINST ILT4, BISPECIFIC ANTI-ILT4/PD-L1 ANTIBODY AND THEIR USES
|
KR20230169230A
(en)
|
2021-04-12 |
2023-12-15 |
브리스톨-마이어스 스큅 컴퍼니 |
Cyclic peptide immunomodulator
|
WO2022221720A1
(en)
|
2021-04-16 |
2022-10-20 |
Novartis Ag |
Antibody drug conjugates and methods for making thereof
|
AU2022261124A1
(en)
|
2021-04-22 |
2023-10-05 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating cancer
|
WO2022235867A2
(en)
|
2021-05-06 |
2022-11-10 |
The Rockefeller University |
Neutralizing anti-sars- cov-2 antibodies and methods of use thereof
|
IL308545A
(en)
|
2021-05-26 |
2024-01-01 |
Oxford Biotherapeutics Ltd |
Pharmaceutical combination comprising an anti-cd205 antibody and an immune checkpoint inhibitor
|
EP4352077A1
(en)
|
2021-06-09 |
2024-04-17 |
Bristol-Myers Squibb Company |
Cyclic peptide immunomodulators
|
WO2022258792A1
(en)
|
2021-06-09 |
2022-12-15 |
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Novel anti-fibrotic drugs
|
WO2023288213A1
(en)
|
2021-07-12 |
2023-01-19 |
Bristol-Myers Squibb Company |
Macrocyclic immunomodulators
|
KR20240035843A
(en)
|
2021-07-19 |
2024-03-18 |
브리스톨-마이어스 스큅 컴퍼니 |
Macrocyclic immunomodulators
|
CN113773401B
(en)
|
2021-09-15 |
2023-06-20 |
宜明昂科生物医药技术(上海)股份有限公司 |
Recombinant fusion protein targeting CD47 and PD-L1 and preparation and application thereof
|
CN113956363B
(en)
|
2021-10-13 |
2023-03-31 |
宜明昂科生物医药技术(上海)股份有限公司 |
Recombinant fusion protein targeting CD47 and CD24 and preparation and application thereof
|
WO2023069994A1
(en)
|
2021-10-20 |
2023-04-27 |
Bristol-Myers Squibb Company |
Immunomodulators
|
WO2023073599A1
(en)
|
2021-10-28 |
2023-05-04 |
Novartis Ag |
Engineered fc variants
|
WO2023077521A1
(en)
|
2021-11-08 |
2023-05-11 |
Celldex Therapeutics, Inc |
Anti-ilt4 and anti-pd-1 bispecific constructs
|
WO2023089314A1
(en)
|
2021-11-18 |
2023-05-25 |
Oxford Biotherapeutics Limited |
Pharmaceutical combinations
|
WO2023102507A1
(en)
|
2021-12-03 |
2023-06-08 |
Bristol-Myers Squibb Company |
Macrocyclic immunomodulators
|
WO2023147399A1
(en)
|
2022-01-27 |
2023-08-03 |
The Rockefeller University |
Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
|
WO2023192873A1
(en)
|
2022-03-28 |
2023-10-05 |
Bristol-Myers Squibb Company |
Macrocyclic immunomodulators
|
EP4257132A1
(en)
|
2022-04-08 |
2023-10-11 |
iOmx Therapeutics AG |
Sik3 inhibitors for treating diseases resistant to death receptor signalling
|
EP4257609A1
(en)
|
2022-04-08 |
2023-10-11 |
iOmx Therapeutics AG |
Combination therapies based on pd-1 inhibitors and sik3 inhibitors
|
WO2023209568A1
(en)
|
2022-04-26 |
2023-11-02 |
Novartis Ag |
Multispecific antibodies targeting il-13 and il-18
|
US11932693B2
(en)
|
2022-05-12 |
2024-03-19 |
BioNTech SE |
Monoclonal antibodies directed against programmed death-1 protein and their use in medicine
|
WO2023225661A1
(en)
|
2022-05-20 |
2023-11-23 |
Bristol-Myers Squibb Company |
Macrocyclic immunomodulators
|
WO2024059472A1
(en)
|
2022-09-12 |
2024-03-21 |
Bristol-Myers Squibb Company |
Macrocyclic immunomodulators
|
US20240101691A1
(en)
|
2022-09-21 |
2024-03-28 |
Sanofi Biotechnology |
Humanized anti-il-1r3 antibody and methods of use
|